1989 INDEX

A

Abdominal
  to gluteal ratio (*see* Waist-to-hips ratio)
  ultrasound in renovascular hypertension, *Mar.*, 171
Acclimatization to heat, *May*, 315
  body fluid volume and, *May*, 326–328
Acetaminophen poisoning: causing lactic acidosis, *Apr.*, 265
Acid-base balance management: in acute renal failure, *Feb.*, 121–122
Acidosis (*see* Lactic acidosis)
Acquired immunodeficiency syndrome-related lymphomas, *Sept.*, 636–638
ACTH (*see* Adrenocorticotropic hormone)
Adenoma: adrenal, differentiated from hyperplasia, *Mar.*, 173–175
Adipose tissue: and obesity, *July*, 475–476
Adolescent: hypertension in, definition of, *Mar.*, 150–153
Adrenal adenoma: differentiated from hyperplasia, *Mar.*, 173–175
Adrenergic-receptor blockers
  alpha- (*see* Alpha-blockers)
  beta- (*see* Beta-blockers)
Adrenocorticotropic hormone
  lung cancer and, small cell, *Dec.*, 794–796
  work in heat and, *May*, 320
Adriamycin in small cell lung cancer, *Dec.*, 803–804, 804–805
  in alternating regimens, *Dec.*, 805
Age
  body mass index and, *July*, 464
  food intake and, *July*, 471
  hypertension awareness, treatment, and control status, by, *Mar.*, 147
  hypertension classification by, *Mar.*, 152
  lymphomas and, non-Hodgkin's *Sept.*, 615
  of onset, classification of obesity by, *July*, 487
Ahlstrom's syndrome: obesity in, *July*, 484
AICD, *June*, 432–433
AIDS-related lymphomas, *Sept.*, 636–638
Alanine-glucose cycles, *Apr.*, 249
Albuterol: in chronic obstructive pulmonary disease, *Oct.*, 697–698
Alcohol
  lactic acidosis due to, *Apr.*, 263
  in porphyria cutanea tarda, *Jan.*, 40
  in protoporphyria, *Jan.*, 42
  restriction in hypertension, *Mar.*, 184
Aldosterone production: and work in heat, *May*, 319–320
Aldosternoism, primary
  diagnosis of, *Mar.*, 172–173, 174
  humoral control of, *Mar.*, 163–164
  treatment of, *Mar.*, 220
Alkalosis: respiratory, in heat stroke, *May*, 352
Alpha-blockers
  in hypertension, *Mar.*, 210–212
  in pulmonary disease, chronic obstructive, *Oct.*, 701
Alpha-methylparatyrosine: in pheochromocytoma, *Mar.*, 221
Ambulatory monitoring
  to guide antiarrhythmic drug therapy, *June*, 427–428
    comparison and combination of electrophysiologic study, *June*, 429–431

1989 INDEX

A

Abdominal
  to gluteal ratio (*see* Waist-to-hips ratio)
  ultrasound in renovascular hypertension, *Mar.*, 171
Acclimatization to heat, *May*, 315
  body fluid volume and, *May*, 326–328
Acetaminophen poisoning: causing lactic acidosis, *Apr.*, 265
Acid-base balance management: in acute renal failure, *Feb.*, 121–122
Acidosis (*see* Lactic acidosis)
Acquired immunodeficiency syndrome-related lymphomas, *Sept.*, 636–638
ACTH (*see* Adrenocorticotropic hormone)
Adenoma: adrenal, differentiated from hyperplasia, *Mar.*, 173–175
Adipose tissue: and obesity, *July*, 475–476
Adolescent: hypertension in, definition of, *Mar.*, 150–153
Adrenal adenoma: differentiated from hyperplasia, *Mar.*, 173–175
Adrenergic-receptor blockers
  alpha- (*see* Alpha-blockers)
  beta- (*see* Beta-blockers)
Adrenocorticotropic hormone
  lung cancer and, small cell, *Dec.*, 794–796
  work in heat and, *May*, 320
Adriamycin in small cell lung cancer, *Dec.*, 803–804, 804–805
  in alternating regimens, *Dec.*, 805
Age
  body mass index and, *July*, 464
  food intake and, *July*, 471
  hypertension awareness, treatment, and control status, by, *Mar.*, 147
  hypertension classification by, *Mar.*, 152
  lymphomas and, non-Hodgkin's *Sept.*, 615
  of onset, classification of obesity by, *July*, 487
Ahlstrom's syndrome: obesity in, *July*, 484
AICD, *June*, 432–433
AIDS-related lymphomas, *Sept.*, 636–638
Alanine-glucose cycles, *Apr.*, 249
Albuterol: in chronic obstructive pulmonary disease, *Oct.*, 697–698
Alcohol
  lactic acidosis due to, *Apr.*, 263
  in porphyria cutanea tarda, *Jan.*, 40
  in protoporphyria, *Jan.*, 42
  restriction in hypertension, *Mar.*, 184
Aldosterone production: and work in heat, *May*, 319–320
Aldosternoism, primary
  diagnosis of, *Mar.*, 172–173, 174
  humoral control of, *Mar.*, 163–164
  treatment of, *Mar.*, 220
Alkalosis: respiratory, in heat stroke, *May*, 352
Alpha-blockers
  in hypertension, *Mar.*, 210–212
  in pulmonary disease, chronic obstructive, *Oct.*, 701
Alpha-methylparatyrosine: in pheochromocytoma, *Mar.*, 221
Ambulatory monitoring
  to guide antiarrhythmic drug therapy, *June*, 427–428
    comparison and combination of electrophysiologic study, *June*, 429–431

for risk assessment of sudden death
after myocardial infarction, *June*, 407–410
after sustained ventricular tachycardia or sudden death, *June*, 415–416
γ-Aminobutyric acid: chemical formula of, *Jan.*, 23
ε-Aminocaproic acid: for coagulation abnormalities in malignancy, *Nov.*, 758
Aminoglycosides: causing acute renal failure, *Feb.*, 112
δ-Aminolevulinic acid
chemical formula of, *Jan.*, 23
dehydrase deficiency causing acute hepatic porphyria, *Jan.*, 36–37
synthase, closed negative-feedback loop controlling, *Jan.*, 17
Aminophylline: in chronic obstructive pulmonary disease, *Oct.*, 696–697
Amphotericin B: causing acute renal failure, *Feb.*, 112–113
Anemia
in cancer
classification of, *Nov.*, 734
evaluation of, *Nov.*, 731–734
peripheral smear in, *Nov.*, 735
of chronic disease, in cancer, *Nov.*, 738–742
differentiated from iron deficiency anemia, *Nov.*, 737
proposed mechanisms for, *Nov.*, 739
hemolytic, in cancer
autoimmune, *Nov.*, 746–748
microangiopathic, *Nov.*, 748–750
of hypersplenism in cancer, *Nov.*, 745–746
hypoproliferative, in cancer, *Nov.*, 734–745
of increased red cell consumption in cancer, *Nov.*, 745–751
iron deficiency, in cancer, *Nov.*, 734–737
cell sizes and shapes in, *Nov.*, 736
differentiated from anemia of chronic disease, *Nov.*, 737
macrocytic, in cancer, *Nov.*, 744
megaloblastic, in cancer, *Nov.*, 745
severe, causing lactic acidosis, *Apr.*, 255
Angiography: pulmonary, in cor pulmonale, *Oct.*, 678
Angioplasty: percutaneous transluminal, in renovascular hypertension, *Mar.*, 217–218
Angiotensin
-converting enzyme inhibitors
in hypertension, *Mar.*, 197, 198–201
in hypertension, renovascular, *Mar.*, 219
in pulmonary disease, chronic obstructive, *Oct.*, 701
-renin system (*see* Renin, -angiotensin system)
during work in heat, *May*, 319–320
Anorectic-reinforcement ratio: for anorectic drugs, *July*, 516
Anthropometric measurements, *July*, 461–464
Antiarrhythmic drugs
FDA-approved, classification of, *June*, 418
in prevention of sudden death after myocardial infarction, *June*, 418–423
arrhythmia variability, *June*, 421
end points of therapy, *June*, 419–421
limitations of therapy, *June*, 419–423
proarrhythmia and, *June*, 422–423
therapeutic trials, *June*, 418–419
in prevention of sudden death after sustained ventricular tachycardia or sudden death, *June*, 426–431

Antiarrhythmic drugs *(cont.)*
combination and comparison of ambulatory monitoring and electrophysiologic study, *June*, 429–431
end points of therapy, *June*, 426–431
hemodynamic stability of sustained VT, *June*, 429
suppression of ambient arrhythmias, *June*, 426–428
suppression of arrhythmia inducibility at electrophysiologic study, *June*, 428–429
therapeutic plasma levels, *June*, 426
Antibodies
antithyroglobulin, *Aug.*, 574–576
antithyroid microsomal, *Aug.*, 574–576
monoclonal (*see* Monoclonal antibody)
thyroid, *Aug.*, 574–577
thyroid-stimulating, *Aug.*, 576–577
Anticholinergic agents: in chronic obstructive pulmonary disease, *Oct.*, 697–698
Anticoagulants
in hypertension, primary pulmonary, *Oct.*, 705–706
in lung cancer, small cell, *Dec.*, 806
Antidiuretic hormone
lung cancer and, small cell, *Dec.*, 793–794
work in heat and, *May*, 321
Anti-inflammatory drugs: nonsteroidal, causing acute renal failure, *Feb.*, 113–114
Anti-ischemic therapy: for prevention of sudden death after myocardial infarction, *June*, 423–425
Antiplatelet drugs: in small cell lung cancer, *Dec.*, 806
Antithyroglobulin antibodies, *Aug.*, 574–576
Antithyroid microsomal antibodies, *Aug.*, 574–576
Aortic stenosis: causing sudden death, *June*, 396
Aplasia: red cell, in malignancy, *Nov.*, 742
Appetite-suppressing drugs, *July*, 511–517
acting on catecholamine neurotransmitters, *July*, 511–515
acting on serotonin neurotransmitters, *July*, 515
anorectic-reinforcement ratio for, *July*, 516
clinical use of, *July*, 511, 514–515
effect on weight loss, *July*, 514
list of, *July*, 512–513
pharmacologic effects of, *July*, 511
safety of, *July*, 515
Arginine vasopressin (*see* Vasopressin)
Arrhythmias
in cor pulmonale, *Oct.*, 676–677
after myocardial infarction, prognostic value of, *June*, 407
ventricular, diuretic-induced, *Mar.*, 189–190
Arsenic exposure: and lung cancer, *Dec.*, 781
Arteries
coronary (*see* Coronary, artery)
pulmonary, enlargement on chest x-rays, *Oct.*, 684, 687
renal, stenosis, arteriographic findings in, *Mar.*, 171
Arteriographic findings: in renal artery stenosis, *Mar.*, 171
Asbestos: and lung cancer, *Dec.*, 781
Aspiration biopsy: fine needle, in thyroid cancer, *Aug.*, 591–592
Aspirin: in small cell lung cancer, *Dec.*, 806
Asthma: severe, causing lactic acidosis, *Apr.*, 255
Atheroembolic disease causing acute renal failure, *Feb.*, 110
contrasted with contrast-media-induced acute renal failure, *Feb.*, 111
ATP-$MgCl_2$: in prevention of acute tubular necrosis, *Feb.*, 119

Atrial natriuretic
factor
in pulmonary disease, chronic obstructive, *Oct.*, 695–696
synthetic, in prevention of acute tubular necrosis, *Feb.*, 119
peptides, and control of blood pressure and volume, *Mar.*, 159
Auscultation: in diagnosis of cor pulmonale, *Oct.*, 690–691
Autonomic function: in essential hypertension, *Mar.*, 155

B

Bardet-Biedl syndrome: obesity in, *July*, 484
BCNU: in small cell lung cancer, *Dec.*, 802–803
Behavioral
modification in hypertension, *Mar.*, 183–184
treatment of obesity, *July*, 505–509
comparison to jaw wiring, *July*, 527
comparison to very low calorie diet, *July*, 526
programs for, *July*, 505–508
self-help programs, *July*, 508
weight loss with, *July*, 507
worksite programs, *July*, 508
Benzocaine: in treatment of obesity, *July*, 518
Beriberi: lactic acidosis in, *Apr.*, 261–262
Beta-blockers
in hypertension, *Mar.*, 202–206
after myocardial infarction, and sudden death, *June*, 423
in obesity, *July*, 518
in pulmonary disease, chronic obstructive, *Oct.*, 697, 701
Beta-carotene: and lung cancer, *Dec.*, 782
Bicarbonate therapy: in lactic acidosis, *Apr.*, 277–282
Biguanides: causing lactic acidosis, *Apr.*, 262–263
Biliointestinal operation: in obesity, *July*, 522, 524
Biliopancreatic bypass: in obesity, *July*, 522, 524–525
Biochemical abnormalities: in porphyria, *Jan.*, 14–20
Biochemistry: of lactic acidosis, *Apr.*, 241–247
Bioelectric impedance analysis: for measuring body fat, *July*, 464–467
Biology: of non-Hodgkin's lymphoma, *Sept.*, 607–612
Biopsy: fine needle aspiration, in thyroid cancer, *Aug.*, 591–592
Blacks, hypertension in
calcium channel blockers in, *Mar.*, 193
labetalol in, *Mar.*, 206
treatment of, *Mar.*, 214
Blood
composition and heat stress, *May*, 325–326
flow
muscle, and work in heat, *May*, 316
peripheral, and work in heat, *May*, 317
renal, and elimination of nitrogenous waste, *Feb.*, 74–75, 76
splanchnic, and work in heat, *May*, 317
pressure
arginine vasopressin and, *Mar.*, 158–159
atrial natriuretic peptides and, *Mar.*, 159
genetic factors in, *Mar.*, 160–162
humoral control of, *Mar.*, 155–166
kallikrein-kinin system and, *Mar.*, 157
in lactic acidosis after carbicarb and bicarbonate, *Apr.*, 281
prostaglandins and, *Mar.*, 157–158
renal sodium handling and, *Mar.*, 159–160

Blood *(cont.)*
renin-angiotensin system and, *Mar.*, 155–156
transfusion (*see* Transfusion)
volume
arginine vasopressin and, *Mar.*, 158–159
atrial natriuretic peptides and, *Mar.*, 159
genetic factors in, *Mar.*, 160–162
humoral control of, *Mar.*, 155–166
kallikrein-kinin system and, *Mar.*, 157
prostaglandins and, *Mar.*, 157–158
renal sodium handling and, *Mar.*, 159–160
renin-angiotensin system and, *Mar.*, 155–156
Body
compartments, isotopic, chemical, and other methods to measure, *July*, 464–467
composition of men and women, *July*, 468
fat (*see* Fat, body)
fluid volume in heat acclimatization, *May*, 326–328
mass index, *July*, 462
age and, *July*, 464
heart disease and, *July*, 479
mortality ratio and, *July*, 477
nomogram for, *July*, 463
weight (*see* Weight)
Bone marrow (*see* Marrow)
Brain radiotherapy: and dementia in small cell lung cancer, *Dec.*, 799–800
BRL 26830A: for obesity, *July*, 518
Bromides: in acute intermittent porphyria, *Jan.*, 34
Bronchitis: chronic, and right ventricular weight and size, *Oct.*, 664
Bronchodilators: in chronic obstructive pulmonary disease, *Oct.*, 696–698
Bubble: gastric, for obesity, *July*, 520
Bullous lesion: on hand in porphyria cutanea tarda, *Jan.*, 38
BUN/creatinine ratio: in acute renal failure, *Feb.*, 103
Burkitt's lymphoma, *Sept.*, 633–636
staging of, *Sept.*, 635
Bypass
biliopancreatic, in obesity, *July*, 522, 524–525
coronary artery, *June*, 424–425
gastric, in obesity, *July*, 522
comparison with jejunoileal bypass, *July*, 524
jejunoileal (*see* Jejunoileal bypass)

C

Caffeine restriction: in hypertension, *Mar.*, 185
Calcitonin: and small cell lung cancer, *Dec.*, 796–797
Calcium
balance management in acute renal failure, *Feb.*, 122
channel blockers
in hypertension, *Mar.*, 193–197
in hypertension, primary pulmonary, *Oct.*, 704
in prevention of acute tubular necrosis, *Feb.*, 119
in pulmonary disease, chronic obstructive, *Oct.*, 702
supplementation, dietary, in hypertension, *Mar.*, 181–182
Cancer
anemia in (*see under* Anemia)
coagulation abnormalities in, *Nov.*, 755–759
clinical manifestations of, *Nov.*, 757–759
hematologic manifestations of, *Nov.*, 731–768
hemolysis in
drug-induced, *Nov.*, 748
immune, *Nov.*, 746–748
hemophagocytic syndrome in, *Nov.*, 751
hypersplenism in, *Nov.*, 745–746
lactic acidosis in, *Apr.*, 258–259

leukocyte abnormalities in, *Nov.*, 753–754
lung, small cell, *Dec.*, 779–825
adrenocorticotropic hormone and, *Dec.*, 794–796
anticoagulant drugs in, *Dec.*, 806
antidiuretic hormone and, *Dec.*, 793–794
antiplatelet drugs in, *Dec.*, 806
calcitonin and, *Dec.*, 796–797
cell of origin of, *Dec.*, 785–786
chemotherapy of (*see* Chemotherapy, of lung cancer)
dementia and, *Dec.*, 799–800
Eaton-Lambert syndrome and, *Dec.*, 800
electron microscopy in, *Dec.*, 785
etiology of, *Dec.*, 779–782
histological transformation, *Dec.*, 786–787
hormonal products and, *Dec.*, 797
management of, clinical, *Dec.*, 811–814
neuromyopathies and, *Dec.*, 797–799
paraneoplastic neurological disorders and, *Dec.*, 797
paraneoplastic syndromes and, *Dec.*, 792–800
pathology of, *Dec.*, 782–787
prevention of, *Dec.*, 781–782
radiation therapy of, *Dec.*, 814
radiation therapy of, combined with chemotherapy, *Dec.*, 809–810
staging, *Dec.*, 787–792
tobacco causing, *Dec.*, 780–781
treatment of, *Dec.*, *800–811*
treatment of, combined modalities, *Dec.*, 809–811
treatment of, current approaches, *Dec.*, 804–811
treatment of, systemic, *Dec.*, 801–804
marrow involvement in, *Nov.*, 743–744
platelet abnormalities in, *Nov.*, 754–755
polycythemia in, *Nov.*, 751–753
red cell aplasia in, *Nov.*, 742
thyroid
biopsy in, fine needle aspiration, *Aug.*, 591–592
scintigraphy in, *Aug.*, 590–591
suppressive therapy in, thyroid function tests after, *Aug.*, 589–590
thyroid function tests in, *Aug.*, 589–592
ultrasonography in, *Aug.*, 591
Captopril
in hypertension, *Mar.*, 199–200
renogram in renovascular hypertension, *Mar.*, 171
Carbicarb: in lactic acidosis, *Apr.*, 281
Carbohydrate: in diet for obesity, *July*, 492
Carbon monoxide poisoning: causing lactic acidosis, *Apr.*, 255
Carboplatin: in small cell lung cancer, *Dec.*, 807
Carcinoma: hepatocellular, and polycythemia, *Nov.*, 752
Cardiac (*see* Heart)
Cardiogenic shock: causing lactic acidosis, *Apr.*, 255
Cardiomegaly: on chest x-ray, *Oct.*, 684, 687, 688
Cardiopulmonary resuscitation, *June*, 432–434
Cardiovascular
adaptations to work in heat, *May*, 319
disease, and heat tolerance, *May*, 336
response, acute, to hard work in heat, *May*, 316–619
system
effect of very low calorie diets on, *July*, 504
function, and obesity, *July*, 478–480
Cardioverter defibrillator: automatic implantable, *June*, 432–433
Carmustine: in small cell lung cancer, *Dec.*, 802–803

β-Carotene: and lung cancer, *Dec.*, 782
Carpenter's syndrome: obesity in, *July*, 484
Catecholamines
lactic acidosis due to, *Apr.*, 265
neurotransmitters, appetite-suppressing drugs acting on, *July*, 511–515
work in heat and, *Mary*, 321
Catheter ablation: of ventricular tachycardia, *June*, 431–432
Cell
of origin of small cell lung cancer, *Dec.*, 785–786
red (*see* Red cell)
T (*see* T cell)
thyrotroph, pituitary, and TSH release, *Aug.*, 558
white cell abnormalities in malignancy, *Nov.*, 753–754
Central nervous system
in heat stroke, *May*, 348
treatment, *May*, 363–364
metastases due to small cell lung cancer, *Dec.*, 791–792
Cerebellar
degeneration in small cell lung cancer, *Dec.*, 800
hemangiomas, and polycythemia, *Nov.*, 752
Charcoal: activated, in protoporphyria, *Jan.*, 45
Chemical methods: for measuring body compartments, *July*, 464–467
Chemicals: in acute hepatic porphyrias, *Jan.*, 25
Chemotherapy
-associated hemolytic-uremic syndrome, *Nov.*, 750–751
drugs
hemolysis due to, *Nov.*, 748
kidney failure due to, acute, *Feb.*, 116
of lung cancer, small cell, *Dec.*, 801–804
alternating, *Dec.*, 805–806
dose intensification, *Dec.*, 807–809
maintenance, *Dec.*, 804–805
new agents and combination, *Dec.*, 806–807
radiotherapy and, *Dec.*, 809–810
of lymphomas
aggressive, *Sept.*, 624–630
aggressive, advanced stage, *Sept.*, 630–631
aggressive, early stage, *Sept.*, 629–630
aggressive, follow-up, *Sept.*, 633
aggressive, salvage therapy, *Sept.*, 631–633
aggressive, summary of, *Sept.*, 633
AIDS-related, *Sept.*, 637–638
Burkitt's, *Sept.*, 635–636
indolent, *Sept.*, 620–624
lymphoblastic, *Sept.*, 640–642
malignant, follicular mixed small and large cell, *Sept.*, 623–624
malignant, follicular, predominantly small cleaved cell, *Sept.*, 622–623
malignant, small lymphocytic consistent with CLL, *Sept.*, 620–622
non-Hodgkin's, *Sept.*, 620–633
of mycosis fungoides, *Sept.*, 643
of Sézary syndrome, *Sept.*, 643
thrombosis and, *Nov.*, 758
Chenodeoxycholic acid: in protoporphyria, *Jan.*, 45
Children
hypertension in, definition of, *Mar.*, 150–153
infant, well, screening for thyroid dysfunction in, *Aug.*, 580
isoniazid poisoning causing lactic acidosis in, *Apr.*, 266
Chloromethylesters: and lung cancer, *Dec.*, 781
Chloroquine: in porphyria cutanea tarda, *Jan.*, 41
Chlorpromazine
in porphyria, acute intermittent, *Jan.*, 32
in prevention of acute tubular necrosis, *Feb.*, 119

Chlorthalidone: in hypertension, in elderly, *Mar.*, 213
Cholesterol: and sudden cardiac death, *June*, 394
Cholestyramine
in obesity, *July*, 519
in protoporphyria, *Jan.*, 45
Chorionic gonadotropin: human, in obesity, *July*, 519–520
Chromate exposure: and lung cancer, *Dec.*, 781
Chromosome changes: in non-Hodgkin's lymphomas, *Sept.*, 610–612
Chronic disease (*see* Anemia, of chronic disease)
Cigarette smoking (*see* Smoking)
Cisplatin plus VP-16: in small cell lung cancer, *Dec.*, 805, 807
Clonazepam: in acute intermittent porphyria, Jan., 34
Clonidine
in hypertension, *Mar.*, 206–208
in hypertensive crisis, *Mar.*, 215
in prevention of acute tubular necrosis, *Feb.*, 119
CNS (*see* Central nervous system)
Coagulation
abnormalities in malignancy, *Nov.*, 755–759
clinical manifestations of, *Nov.*, 757–759
disorders in heat stroke, *May*, 349–350
Cohen's syndrome: obesity in, *July*, 484
Coma: nonketotic hyperosmolar, in heat stroke, treatment of, *May*, 363
Computed tomography
in diagnosis of liver metastases in small cell lung cancer, *Dec.*, 789
in lung cancer, small cell, *Dec.*, 812
thyroid, *Aug.*, 574
Conduction: definition of, *May*, 314
Contraceptives: oral, causing hypertension, *Mar.*, 169–170
Convection: definition of, *May*, 314
Cooling unit: in heat stroke, *May*, 359
Coproporphyria, hereditary, *Jan.*, 35–36
features of, clinical and biochemical, *Jan.*, 35
genetics of, *Jan.*, 35
incidence of, *Jan.*, 35
metabolic defect in, *Jan.*, 35
treatment of, *Jan.*, 35–36
Coproporphyrinogen oxidase deficiency: in hereditary coproporphyria, *Jan.*, 35
Cor pulmonale, *Oct.*, 663–718
(*See also* Pulmonary disease, chronic obstructive)
arrhythmias in, *Oct.*, 676–677
cardiac examination in diagnosis of, *Oct.*, 683–691
case histories, *Oct.*, 683–685
classification according to causative factor, *Oct.*, 660
diagnosis of
auscultation in, *Oct.*, 690–691
neck veins in, *Oct.*, 688–689
palpitation of cardiac impulse in, *Oct.*, 689–690
precordium inspection in, *Oct.*, 689
echocardiography in, *Oct.*, 679–683
electrocardiogram in, *Oct.*, 672–677
heart function in, right, *Oct.*, 667–669
hemodynamics in, *Oct.*, 669–672
measurements of flow, pressure, and resistance in, *Oct.*, 667–669
pathology of, *Oct.*, 663–666
pathophysiology of, *Oct.*, 666–672
pulmonary vascular bed in, *Oct.*, 667–669
radiography in, *Oct.*, 677–678
treatment of, *Oct.*, 691–693
Cori cycle, *Apr.*, 246
Coronary
artery
bypass grafting, *June*, 424–425
disease, and sudden death, *June*, 395

Coronary *(cont.)*
occlusion, thrombotic, and sudden death, *June*, 395
vasculature abnormalities, and sudden death, *June*, 396
Corticosteroids: in chronic obstructive pulmonary disease, *Oct.*, 694
Cortisol: and obesity, *July*, 482
Cost: of obesity treatment, *July*, 525, 528
Coumadin
in coagulation abnormalities in malignancy, *Nov.*, 758
in lung cancer, small cell, *Dec.*, 806
Cramps, heat, *May*, 329–332
clinical features of, *May*, 332
Creatinine
BUN/creatinine ratio in acute renal failure, *Feb.*, 103
heat stress and, *May*, 325
ratio, urinary to plasma, in acute renal failure, *Feb.*, 101
serum
concentration, relation to glomerular filtration rate, *Feb.*, 107
triphasic change in acute tubular necrosis, *Feb.*, 106
Creatinuria: after heat cramps, *May*, 332
CT (*see* Computed tomography)
Cushing's syndrome: and small cell lung cancer, *Dec.*, 794–796
Cutaneous (*see* Skin)
Cyanide ingestion: causing lactic acidosis, *Apr.*, 265–266
Cyclophosphamide in small cell lung cancer, *Dec.*, 801–802, 804–805
in alternating regimens, *Dec.*, 805
Cyclosporine: causing acute renal failure, *Feb.*, 114
Cytochrome P-450: in porphyria cutanea tarda, *Jan.*, 40

D

Dantrolene
in hyperthermia, malignant, *May*, 355–356
in neuroleptic malignant syndromes, *May*, 357
Death (*see* Mortality)
Defibrillation, *June*, 432–434
Defibrillator: automatic implantable cardioverter, *June*, 432–433
Dementia: and small cell lung cancer, *Dec.*, 799–800
Diabetes mellitus
hypertension in, treatment of, *Mar.*, 213–214
lactic acidosis in, *Apr.*, 256
obesity and, *July*, 480–481
sudden cardiac death and, *June*, 394
Dialysis
in lactic acidosis, *Apr.*, 283–284
in renal failure, acute, *Feb.*, 123–124
Dichloroacetate: in lactic acidosis, *Apr.*, 282–283
Diet
calcium supplementation in, in hypertension, *Mar.*, 181–182
for obesity (*see* Obesity, diet for)
potassium supplementation in, in hypertension, *Mar.*, 182–183
sodium restriction in, in hypertension, *Mar.*, 180–181
special, in hypertension, *Mar.*, 185
Diltiazem: in primary pulmonary hypertension, *Oct.*, 704
Dinitrophenol: in obesity, *July*, 518
Diphenylhydantoin: for obesity, *July*, 516
Diuresis: solute, in prevention of acute tubular necrosis, *Feb.*, 117–119
Diuretics
in hypertension, *Mar.*, 188–192, 194–195
in pulmonary disease, chronic obstructive, *Oct.*, 695–696
Dopamine: in prevention of acute tubular necrosis, *Feb.*, 119
Doppler echocardiography: in cor pulmonale *Oct.*, 680–683
Doxazosin: in hypertension, *Mar.*, 211

Doxorubicin in small cell lung cancer, *Dec.*, 803–804, 804–805
in alternating regimens, *Dec.*, 805
Drugs
affecting gastrointestinal tract, in obesity, *July*, 518–519
antiarrhythmic (*see* Antiarrhythmic drugs)
anti-inflammatory, nonsteroidal, causing acute renal failure, *Feb.*, 113–114
antiplatelet, in small cell lung cancer, *Dec.*, 806
appetite-suppressing (*see* Appetite-suppressing drugs)
associated with decreased peripheral conversion of T_4 to T_3, *Aug.*, 556
centrally acting, in hypertension, *Mar.*, 206–210
left ventricular hypertrophy and, *Mar.*, 209–210
chemotherapy (*see* Chemotherapy, drugs)
effect on thyroid-binding globulins, *Aug.*, 555
heat stroke and, *May*, 337, 338
interfering with T_4 and T_3 binding to thyroid binding proteins, *Aug.*, 556
lactic acidosis due to, *Apr.*, 262–268
metabolism alterations in acute renal failure, management of, *Feb.*, 125
for obesity, *July*, 511–520
in porphyrias, acute hepatic, *Jan.*, 25
thermogenic, for obesity, *July*, 517–518

E

Eaton-Lambert syndrome: and small cell lung cancer, *Dec.*, 800
Echocardiography
in cor pulmonale, *Oct.*, 679–683
in hypertension, pulmonary, *Oct.*, 679–683
Edema: heat, *May*, 329
Elderly
heat stroke in, mortality of, *May*, 358
hypertension in
calcium channel blockers in, *Mar.*, 193
labetalol in, *Mar.*, 206
treatment of, *Mar.*, 213
Electrocardiogram
abnormalities in heat stroke, treatment of, *May*, 363
in cor pulmonale, *Oct.*, 672–677
signal-averaged
for risk assessment of sudden death after myocardial infarction, *June*, 410–412
supporting substrate hypothesis of sudden cardiac death, *June*, 401, 402–403
of ventricular hypertrophy, right, *Oct.*, 686
Electrolyte balance: in acute renal failure, management of, *Feb.*, 120–121
Electron microscopy: in small cell lung cancer, *Dec.*, 785
Electrophysiologic studies
to guide antiarrhythmic drug therapy
comparison and combination of ambulatory monitoring, *June*, 429–431
limitations of, *June*, 429
in sudden death
for risk assessment after myocardial infarction, *June*, 412–414
for risk assessment after sustained ventricular tachycardia, *June*, 416–417
supporting substrate hypothesis, *June*, 401, 404
Electrophysiology: of substrate, in substrate hypothesis of sudden death, *June*, 399–404
Emphysema: right ventricular weight and size in, *Oct.*, 664
Enalapril: in hypertension, *Mar.*, 200–201

Endocardial mapping: in substrate hypothesis of sudden death, *June*, 400–401
Endocarditis: nonbacterial thrombotic, in cancer, *Nov.*, 757–758
Endocrine
  adaptations to heat, *May*, 319–321
  changes in obesity, *July*, 481–482
  hyperthermia, *May*, 353–354
Energy
  content in men and women, *July*, 468
  expenditure
    components of, *July*, 472
    obesity and, *July*, 471–472
    relation to body weight and activity level, *July*, 496
  needs
    basal, *July*, 498
    estimation of, *July*, 493
Environmental heat illness, *May*, 329
Enzyme
  defects in porphyria, *Jan.*, 16, 19–20
  inhibitors
    angiotensin-converting (*see* Angiotensin,-converting enzyme inhibitors)
    in obesity, *July*, 519
Ephedrine: for obesity, *July*, 517
Epinephrine
  lactic acidosis due to, *Apr.*, 265
  poisoning, lactic acidosis in, *Apr.*, 261
Epsilon-aminocaproic acid: in coagulation abnormalities in malignancy, *Nov.*, 758
Erythropoiesis: model of, *Nov.*, 741
Erythropoietic porphyria (*see* Porphyria, erythropoietic)
Estrogen: role in porphyria cutanea tarda, *Jan.*, 40
Ethanol (*see* Alcohol)
Ethylene glycol: causing lactic acidosis, *Apr.*, 263
Examination (*see* Physical examination)
Exercise
  in hypertension, *Mar.*, 183
  for obesity, *July*, 509–510
  sudden cardiac death and, *June*, 394–395
Exertion-induced heat stroke (*see* Heat, stroke, exertional)

F

Facial hair: in porphyria cutanea tarda, *Jan.*, 38
Fat
  body
    definition of, *July*, 461–467
    distribution of, *July*, 461–467
    distribution of, and health risks, *July*, 477–478
    distribution of, percentiles for, *July*, 466, 467
    measurement of, *July*, 461–467
  mobilization, regional, in obesity, *July*, 520
Fenfluramine: in obesity, *July*, 527
Ferrochelatase deficiency
  in porphyria, *Jan.*, 19
    variegate, *Jan.*, 36
  in protoporphyria, *Jan.*, 43
Fiber: in treatment of obesity, *July*, 518–519
Fluid
  balance in acute renal failure, management of, *Feb.*, 120–121
  volume in heat acclimatization, *May*, 326–328
Food
  intake, and obesity, *July*, 470–471
  subdivision within each food group by relative nutritional value, *July*, 502–503
  thermogenic effects of, *July*, 474–475
Football player: heat stroke in, *May*, 343–344
Fructose
  lactic acidosis due to, *Apr.*, 263–264
  -1,6-diphosphatase deficiency causing lactic acidosis, *Apr.*, 266

FT_3 (*see* Triiodothyronine, free)
FT_4 (*see* Thyroxine, free)

G

Gallbladder disease: and obesity, *July*, 481
Gastric
  bubble for obesity, *July*, 520
  bypass in obesity, *July*, 522
    comparison with jejunoileal bypass, *July*, 524
  operations in obesity, *July*, 522–524
Gastrointestinal
  procedures in obesity, *July*, 521–522
  tract, drugs affecting, in obestiy, *July*, 518–519
Genetic
  analysis, molecular, of non-Hodgkin's lymphomas, *Sept.*, 610–612
  factors
    in control of blood pressure and volume, *Mar.*, 160–162
    in obesity, *July*, 483–485
Genetics
  of coproporphyria, hereditary, *Jan.*, 35
  of porphyria
    cutanea tarda, *Jan.*, 37
    erythropoietic, congenital, *Jan.*, 46
    intermittent, acute, *Jan.*, 29
    variegate, *Jan.*, 36
  of protoporphyria, *Jan.*, 42
Glomerular filtration
  fraction related to salt and water reabsorption in elimination of nitrogenous waste, *Feb.*, 76–80
  rate
    elimination of nitrogenous waste and, *Feb.*, 75–76, 77
    relation to serum creatinine concentration, *Feb.*, 107
Gluconeogenesis, *Apr.*, 242
Glucose
  -alanine cycles, *Apr.*, 249
  -6-phosphatase deficiency causing lactic acidosis, *Apr.*, 266
  tolerance, and diuretics, *Mar.*, 191
Gluteal-to-abdominal ratio (*see* Waist-to-hips ratio)
Glycogenolysis, *Apr.*, 242
Glycolysis, *Apr.*, 241–242
  phases of, *Apr.*, 242, 243
Glycosides: cardiac, interaction with calcium channel blockers, *Mar.*, 196
Gonadotropin: human chorionic, in obesity, *July*, 519–520
Growth hormone
  obesity and, *July*, 481
  therapy in obesity, *July*, 518
  work in heat and, *May*, 320
Guanabenz: in hypertension, *Mar.*, 209
Guanfacine: in hypertension, *Mar.*, 208
Guanidine: in Eaton-Lambert syndrome in small cell lung cancer, *Dec.*, 800

H

Hair: facial, in porphyria cutanea tarda, *Jan.*, 38
Haloperidol: causing neuroleptic malignant syndrome, *May*, 356
Hand lesions: in porphyria cutanea tarda, *Jan.*, 38
Health risks
  fat distribution and, *July*, 477–478
  overweight and, *July*, 476–477
Heart
  death (*see* Sudden death, cardiac)
  disease
    electrical, causing sudden death, *June*, 396
    relation to body mass index and skinfold thickness, *July*, 479
  examination in diagnosis of cor pulmonale, *Oct.*, 683–691
  glycosides, interaction with calcium channel blockers, *Mar.*, 196

Heart *(cont.)*
impulse palpitation in diagnosis of cor pulmonale, *Oct.*, 689–690
-lung transplant in primary pulmonary hypertension, *Oct.*, 705
output
bicarbonate therapy in lactic acidosis and, *Apr.*, 278, 279
during work in heat, *May*, 319
rate during work in heat, *May*, 319
right, function in cor pulmonale, *Oct.*, 667–669
Heat
acclimatization, *May*, 315
body fluid volume and, *May*, 326–328
cramps, *May*, 329–332
clinical features of, *May*, 332
edema, *May*, 329
exhaustion, *May*, 332–334
salt depletion causing, *May*, 333–334
treatment of, *May*, 334
water depletion causing, *May*, 332–333
hyperpyrexia, *May*, 339
illness, environmental, *May*, 329
intolerance, *May*, 336
in recovered heat stroke patients, *May*, 352–353
physiological responses to, *May*, 315–328
production during various activities, *May*, 316
prostration (*see*, exhaustion *above*)
stress, *May*, 313–377
blood composition and, *May*, 325–326
renal function response to, *May*, 324–325
stroke, *May*, 313, 335–364
central nervous system dysfunction in, treatment of, *May*, 363–364
classic, *May*, 339–342
classic, comparison to exertional, *May*, 340
clinical manifestations of, *May*, 339
coma in, nonketotic hyperosmolar, treatment of, *May*, 363
complications, treatment of, *May*, 360–364
diagnosis of, differential, *May*, 353
drugs increasing risk of, *May*, 337, 338
ECG abnormalities in, treatment of, *May*, 363
exertional, *May*, 342–346
exertional, comparison to classic, *May*, 340
exertional, and rhabdomyolysis in women, *May*, 346
hyperkalemia in, treatment of, *May*, 362
hypernatremia in, treatment of, *May*, 363
hyperthyroidism and, *May*, 354
hyperuricemia in, treatment of, *May*, 363
hypocalcemia in, treatment of, *May*, 363
hypoglycemia in, treatment of, *May*, 362
pathology of, *May*, 346–352
patients, recovered, heat intolerance in, *May*, 352–353
pheochromocytoma storm and, *May*, 354–355
potassium deficiency and, *May*, 337–339
predisposing factors, *May*, 335–337
prognosis, *May*, 364
renal failure in, acute, treatment of, *May*, 361–362
rhabdomyolysis in, treatment of, *May*, 361
treatment of, *May*, 357–364
treatment of, general measures, *May*, 358–360
syncope, *May*, 329
tetany, *May*, 329
thermoregulation in, *May*, 313–314

work in
adaptation to, *May*, 315–328
cardiovascular adaptations to, *May*, 319
endocrine adaptations to, *May*, 319–321
hard, acute cardiovascular response to, *May*, 316–319
sweat volume and composition during, *May*, 321–324
Hemangioma: cerebellar, and polycythemia, *Nov.*, 752
Hematin in porphyria
erythropoietic, congenital, *Jan.*, 47
intermittent, acute, *Jan.*, 32–33
for seizures, *Jan.*, 34
Hematocrits: reticulocyte maturation index for, *Nov.*, 733
Hematologic manifestations: of malignancy, *Nov.*, 731–768
Heme
arginate in acute intermittent porphyria, *Jan.*, 33
biosynthesis in porphyria, *Jan.*, 14–18
pathway, *Jan.*, 16
intravenous
in porphyria, acute intermittent, *Jan.*, 32–33
in protoporphyria, *Jan.*, 45
structure of, *Jan.*, 15
synthesis, closed negative-feedback loop controlling, *Jan.*, 17
Hemochromatosis: and porphyria cutanea tarda, *Jan.*, 38
Hemodynamic changes in acute tubular necrosis, *Feb.*, 89–91
pathogenic significance of, *Feb.*, 90
Hemodynamics
in cor pulmonale, *Oct.*, 669–672
in hypertension
essential, *Mar.*, 153–154
pulmonary, primary, *Oct.*, 673
in pulmonary disease, chronic obstructive, *Oct.*, 670
Hemoglobinuric acute renal failure, *Feb.*, 110–112
Hemolysis
chemotherapeutic drugs causing, *Nov.*, 748
immune, in malignancy, *Nov.*, 746–748
in porphyria, congenital erythropoietic, *Jan.*, 46
Hemolytic
anemia (*see* Anemia, hemolytic)
-uremic syndrome, chemotherapy-associated, *Nov.*, 750–751
Hemophagocytic syndrome: in cancer, *Nov.*, 751
Hemorrhage: in malignancy, *Nov.*, 756
Heparin: in disseminated intravascular coagulation in malignancy, *Nov.*, 758
Hepatic
(*See also* Liver)
porphyria (*see* Porphyria, hepatic)
Hepatitis: fulminant, lactic acidosis in, *Apr.*, 256
Hepatobiliary disease: and acute renal failure, *Feb.*, 108–109
Hepatocellular carcinoma: and polycythemia, *Nov.*, 752
Hepatoerythropoietic porphyria, *Jan.*, 41–42
Hepatorenal syndrome, *Feb.*, 108
Hips (*see* Waist-to-hips ratio)
History: medical, in hypertension diagnosis, *Mar.*, 166
Homosexual men: non-Hodgkin's lymphoma in, *Sept.*, 637
Hormone
adrenocorticotropic (*see* Adrenocorticotropic hormone)
antidiuretic (*see* Antidiuretic hormone)
growth (*see* Growth hormone)
luteinizing hormone-releasing hormone in acute intermittent porphyria, *Jan.*, 34
products and small cell lung cancer, *Dec.*, 797
thyroid (*see* Thyroid, hormone)
thyroid-stimulating, *Aug.*, 577–578

Hormone *(cont.)*
release, and pituitary thyrotroph cell, *Aug.*, 558
thyrotropin-releasing, *Aug.*, 569–570
challenge tests, *Aug.*, 578–580
Humoral control
of aldosteronism, primary, *Mar.*, 163–164
of blood pressure and volume, *Mar.*, 155–166
of hypertension
malignant, *Mar.*, 165–166
renovascular, *Mar.*, 162–163
secondary, *Mar.*, 162–165
of pheochromocytoma, *Mar.*, 164–165
Hydralazine
in hypertension, *Mar.*, 212–213
pulmonary, primary, *Oct.*, 703–704
in pulmonary disease, chronic obstructive, *Oct.*, 701–702
Hypercalcemia
in heat stroke, *May*, 351
lung cancer and, small cell, *Dec.*, 797
renal failure and, acute, *Feb.*, 115
Hyperkalemia
in heat stroke, treatment of, *May*, 362
in lactic acidosis, *Apr.*, 275
Hyperlactatemia, *Apr.*, 247
stress, *Apr.*, 261
Hypernatremia: in heat stroke, treatment of, *May*, 363
Hyperosmolar coma: nonketotic, in heat stroke, treatment of, *May*, 363
Hyperphosphatemia
in heat stroke, *May*, 351
in lactic acidosis, *Apr.*, 275–276
Hyperplasia: adrenal, differentiated from adenoma, *Mar.*, 173–175
Hyperpyrexia: heat, *May*, 339
Hypersplenism: anemia of, in cancer, *Nov.*, 745–746
Hypertension, *Mar.*, 145–232
accelerated (*see* malignant *below*)
in adolescent, definition of, *Mar.*, 150 153
alcohol restriction in, *Mar.*, 184
alpha-adrenergic-receptor blockers in, *Mar.*, 210–212
angiotensin-converting enzyme inhibitors in, *Mar.*, 197, 198–201
awareness, by race, sex, and age, *Mar.*, 147
behavioral modification in, *Mar.*, 183–184
beta-blockers in, *Mar.*, 202–206
borderline, definition of, *Mar.*, 150
caffeine restriction in, *Mar.*, 185
calcium channel blockers in, *Mar.*, 193–197
calcium supplementation in, dietary, *Mar.*, 181–182
in children, definition of, *Mar.*, 150–153
classification, by age group, *Mar.*, 152
control status by race, sex, and age, *Mar.*, 147
definitions, *Mar.*, 147–153
diagnosis of, *Mar.*, 166–178
scheme for, *Mar.*, *149*
diet in, special, *Mar.*, 185
diuretics in, *Mar.*, 188–192, 194–195
drugs in
(*See also* Hypertension, treatment, pharmacologic *below*)
centrally active, *Mar.*, 206–210
centrally active, and left ventricular hypertrophy, *Mar.*, 209–210
essential
autonomic function in, *Mar.*, 155
definition of, *Mar.*, 150
hemodynamics in, *Mar.*, 153–154
etiology of, *Mar.*, 153–155
exercise in, *Mar.*, 183
follow-up criteria for first-occasion measurement, *Mar.*, 149
history in, medical, *Mar.*, 166

initial evaluation in, *Mar.*, 166
labile, definition of, *Mar.*, 150
laboratory evaluation in, *Mar.*, 168–169
malignant
definition of, *Mar.*, 150
humoral control of, *Mar.*, 165–166
obesity and, *July*, 478–480
oral contraceptive-induced, *Mar.*, 169–170
pathogenesis of, *Mar.*, 153–155
percentage of population with, *Mar.*, 148
percentage of population with, *Mar.*, 148
physical examination in, *Mar.*, 166–168
potassium supplementation in, *Mar.*, 182–183
in pregnancy, *Mar.*, 153
prevalence in U.S., *Mar.*, 146
primary (*see* essential *above*)
pulmonary, primary
anticoagulants in, *Oct.*, 705, 706
calcium channel blockers in, *Oct.*, 704
echocardiography in, *Oct.*, 679–683
hemodynamics in, *Oct.*, 673
hydralazine in, *Oct.*, 703–704
prostacyclin in, *Oct.*, 704–705
radiography in, *Oct.*, 678
transplantation in, *Oct.*, 705
treatment of, *Oct.*, 702–707
treatment strategy, *Oct.*, 705–707
vasodilators in, *Oct.*, 702–705
pulmonary, thromboembolic, chronic
echocardiography in, *Oct.*, 679–683
radiography in, *Oct.*, 678
results of surgical intervention in, *Oct.*, 672
treatment of, *Oct.*, 707
renovascular
angioplasty in, percutaneous transluminal, *Mar.*, 217–218
clinical characteristics of, *Mar.*, 170
diagnosis of, *Mar.*, 170–172
diagnosis of, definitive tests, *Mar.*, 171–172
humoral control of, *Mar.*, 162–163
pharmacologic screening in, *Mar.*, 171
pyelogram in, *Mar.*, 170
screening tests in, *Mar.*, 170–171
surgery in, *Mar.*, 218–219
treatment of, *Mar.*, 217–220
treatment of, medical, *Mar.*, 219–220
ultrasound in, abdominal, *Mar.*, 171
secondary
causes of, *Mar.*, 151
definition of, *Mar.*, 150
evaluation of patients for, *Mar.*, 169
humoral control of, *Mar.*, 162–165
treatment of, *Mar.*, 217–221
smoking cessation in, *Mar.*, 185
sodium restriction in, dietary, *Mar.*, 180–181
sympatholytic agents in, *Mar.*, 202–206
systemic, definition of, *Mar.*, 147
treatment of, *Mar.*, 178–179
in blacks, *Mar.*, 214
in diabetics, *Mar.*, 213–214
in elderly, *Mar.*, 213
nonpharmacologic, *Mar.*, 179–185
nonpharmacologic, overall recommendations for, *Mar.*, 185
percentage receiving medication, *Mar.*, 148
pharmacologic, *Mar.*, 186–188
pharmacologic, stepped-care program, *Mar.*, 187
by race, sex, and age, *Mar.*, 147
vasodilators in, *Mar.*, 204–205, 212–213
weight reduction in, *Mar.*, 179–180

Hypertensive crisis
diagnosis of, *Mar.*, 177–178
treatment of, *Mar.*, 214–216
Hyperthermia
endocrine, *May*, 353–354
"hypothalamic," *May*, 357
malignant, *May*, 355–356
with sepsis in myelopathy patients, *May*, 353
Hyperthyroidism
causes of, *Aug.*, 582
diagnosis
differential, thyroid function tests in, *Aug.*, 582–583
thyroid function tests in, *Aug.*, 581–583
heat stroke and, *May*, 354
TRH challenge test results in, *Aug.*, 579
Hypertrophy, ventricular
left, and centrally acting drugs in hypertension, *Mar.*, 209–210
right
on chest x-rays, *Oct.*, 684, 687
electrocardiogram of, *Oct.*, 686
Hyperuricemia
in heat stroke, treatment of, *May*, 363
in lactic acidosis, *Apr.*, 275–276
management in acute renal failure, *Feb.*, 122
Hypocalcemia in heat stroke, *May*, 350–351
treatment of, *May*, 363
Hypocapnia: in lactic acidosis, *Apr.*, 276
Hypochloremia: in lactic acidosis, *Apr.*, 275
Hypoglycemia
in heat stroke, *May*, 344, 352
treatment of, *May*, 362
lactic acidosis due to, *Apr.*, 267, 268
lactic acidosis of malignancy and, *Apr.*, 258
Hypokalemia: in heat stroke, treatment of, *May*, 362
Hypoperfusion: regional, causing lactic acidosis, *Apr.*, 255
Hypophosphatemia: in heat stroke, *May*, 351–352
Hypoproliferative anemias: in cancer, *Nov.*, 734–745
Hypotension: avoidance in acute renal failure, *Feb.*, 125–126
Hypothalamic
hyperthermia, *May*, 357
obesity, *July*, 486
Hypothyroidism
causes of, *Aug.*, 583
diagnosis, thyroid function tests in, *Aug.*, 583–585
in symptomatic ambulatory patient, *Aug.*, 585
TRH challenge test results in, *Aug.*, 579
Hypoventilation-obesity syndrome, *July*, 481
Hypovolemic shock; causing lactic acidosis, *Apr.*, 255
Hypoxemia: profound, causing lactic acidosis, *Apri.*, 255

I

Imaging
magnetic resonance (*see* Magnetic resonance imaging)
thyroid (*see* Thyroid, imaging)
Immune hemolysis: in malignancy, *Nov.*, 746–748
Immunodeficiency syndrome: acquired, lymphomas related to, *Sept.*, 636–638
Inborn errors of metabolism: causing lactic acidosis, *Apr.*, 266–268
Infant: well, screening for thyroid dysfunction in, *Aug.*, 580
Infarction (*see* Myocardial, infarction)
Influenza vaccine: in chronic obstructive pulmonary disease, *Oct.*, 694
Interferon: alpha, in mycosis fungoides and Sézary syndrome, *Sept.*, 643–644
Interleukin-2: in small cell lung cancer, *Dec.*, 811

Iodine
metabolism and thyroid hormone, *Aug.*, 553–554
uptake test, radioactive thyroid, *Aug.*, 571–572
Ipratropium bromide: in chronic obstructive pulmonary disease, *Oct.*, 697–698
Iron
deficiency anemia (*see* Anemia, iron deficiency)
overload in porphyria cutanea tarda, *Jan.*, 40
therapy, oral, in protoporphyria, *Jan.*, 45
Isoniazid poisoning: causing lactic acidosis, *Apr.*, 266
Isotopic methods: for measuring body compartments, *July*, 464–467

J

Jaw wiring for obesity, *July*, 520–521
comparison to behavioral treatment, *July*, 527
Jejunoileal bypass in obesity, *July*, 522, 524–525
comparison with gastric bypass, *July*, 524
lactic acidosis due to, *Apr.*, 267–268
Jugular venous pulse: in cor pulmonale, *Oct.*, 689
Juxtaglomerular apparatus: and control of renin release, *Mar.*, 156

K

Kallikrein-kinin system
control of blood pressure and volume and, *Mar.*, 157
interaction with renin-angiotensin and prostaglandin systems, *Mar.*, 158
Kidney
(*See also* Renal)
blood flow, and elimination of nitrogenous waste, *Feb.*, 74–75, 76
cortical necrosis, *Feb.*, 109
damage in heat stroke, *May*, 347–348
disease, chronic, acute renal failure superimposed on, *Feb.*, 107
failure, acute, *Feb.*, 71–132
acid-base balance management in, *Feb.*, 121–122
aminoglycosides causing, *Feb.*, 112
amphotericin B causing, *Feb.*, 112–113
angiotensin-converting enzyme inhibitors causing, *Mar.*, 198
atheroembolic disease causing, *Feb.*, 110
atheroembolic disease causing, contrasted with contrast-media-induced acute renal failure, *Feb.*, 111
BUN/creatinine ratio in, *Feb.*, 103
calcium balance management in, *Feb.*, 122
chemotherapeutic agents causing, *Feb.*, 116
classification of, anatomical and pathophysiologic, *Feb.*, 71–74
cyclosporine causing, *Feb.*, 114
dialysis in, *Feb.*, 123–124
differential diagnosis, *Feb.*, 97–104
differential diagnosis, summary of, *Feb.*, 105
drug metabolism alterations in, management of, *Feb.*, 125
electrolyte balance management in, *Feb.*, 120–121
established, management of, *Feb.*, 119–126
excretory dysfunction during, pathophysiology, *Feb.*, 86
fluid balance management in, *Feb.*, 120–121
fractional excretion of sodium in, *Feb.*, 101–103

Kidney *(cont.)*
in heat stroke, treatment of, *May*, 361–362
hemoglobinuric, *Feb.*, 110–112
hepatobiliary disease and, *Feb.*, 108–109
history in, *Feb.*, 97
hypercalcemia and, *Feb.*, 115
hyperuricemia management in, *Feb.*, 122
hypotension in, avoidance of, *Feb.*, 125–126
intrinsic (parenchymal), pathophysiology, *Feb.*, 83–96
large vessel occlusion causing, *Feb.*, 83
management of, *Feb.*, 119–126
microvascular disease causing, *Feb.*, 83–84
in myeloma, multiple, *Feb.*, 114–115
myoglobinuric, *Feb.*, 110–112
neoplastic disorders associated with, *Feb.*, 114–116
nephrotoxic injuries in, avoidance of, *Feb.*, 125–126
nifedipine causing, *Mar.*, 196
nonsteroidal anti-inflammatory drugs causing, *Feb.*, 113–114
nutritional considerations in, *Feb.*, 124–125
obstructive (postrenal), exclusion of, *Feb.*, 98
obstructive (postrenal), pathophysiology of, *Feb.*, 80–81
pathophysiology of, *Feb.*, 80–96
phosphorus balance management in, *Feb.*, 122
physical examination in, *Feb.*, 97
postoperative, *Feb.*, 116
potassium metabolism management in, *Feb.*, 121
prerenal, pathophysiology of, *Feb.*, 81–83
prognosis, *Feb.*, 126–127
radiocontrast-media-induced, *Feb.*, 113
radiocontrast-media-induced, contrasted with atheroembolic-induced acute renal failure, *Feb.*, 111
sepsis and, *Feb.*, 108
superimposed on chronic renal disease, *Feb.*, 107
syndromes of, *Feb.*, 106–116
tubular necrosis syndromes and, acute, *Feb.*, 109
uremia complications in, management of, *Feb.*, 122–123
uric acid nephropathy causing, acute, *Feb.*, 116
urinary "diagnostic indices" in, *Feb.*, 98–99, 100–101
urinary Na concentration in, *Feb.*, 99
urinary osmolality in, *Feb.*, 99, 101
urinary to plasma creatinine ratio in, *Feb.*, 101
urine volumes in, *Feb.*, 97
functional response to heat stress, *May*, 324–325
hepatorenal syndrome, *Feb.*, 108
microvascular disease causing acute renal failure, *Feb.*, 83–84
sodium handling, and control of blood pressure and volume, *Mar.*, 159–160
success, concept of "acute renal success," *Feb.*, 91–95
tubule (*see* Tubular)
Kinin (*see* Kallikrein-kinin system)

L

Labetalol
in hypertension, *Mar.*, 203–206
in hypertensive crisis, *Mar.*, 216
Laboratory evaluation: in hypertension diagnosis, *Mar.*, 168–169
Lactate
concentration, blood
algorithm for evaluation of, *Apr.*, 274
effects of carbicarb and bicarbonate on, *Apr.*, 281
prognosis in lactic acidosis and, *Apr.*, 285, 286

metabolism
disorders, classification and etiologies of, *Apr.*, 253–268
effect of dichloroacetate on, *Apr.*, 282
production of, *Apr.*, 247–253
shuttle, *Apr.*, 250
utilization of, *Apr.*, 247–253
Lactic acid cycles, *Apr.*, 249
Lactic acidosis, *Apr.*, 241–300
bicarbonate in, *Apr.*, 281
biochemistry of, *Apr.*, 241–247
carbicarb in, *Apr.*, 281
causes of (Cohen and Woods' classification), *Apr.*, 254
congenital, *Apr.*, 266
D, *Apr.*, 267–268
diagnosis of, *Apr.*, 269–276
history of, *Apr.*, 241
hypoglycemic, *Apr.*, 268
prognosis, *Apr.*, 284–285
treatment of, *Apr.*, 276–284
type A, *Apr.*, 253–254
causes of, *Apr.*, 254–255
type B, *Apr.*, 253–254
causes of, *Apr.*, 255–267
Leukemia
lactic acidosis in, *Apr.*, 258
T cell leukemia/lymphoma, retrovirus associated adult, *Sept.*, 644–646
Leukocyte abnormalities: in malignancy, *Nov.*, 753–754
Leukocytosis: in lactic acidosis, *Apr.*, 276
Lipectomy: suction-assisted, in obesity, *July*, 521
Lipids: and diuretics, *Mar.*, 190–191
Liposuction: in obesity, *July*, 521
Lisinopril: in hypertension, *Mar.*, 201
Lithium carbonate: causing neuroleptic malignant syndrome, *May*, 356
Liver
damage in heat stroke, *May*, 348–349
disease
lactic acidosis in, *Apr.*, 256–258
in protoporphyria, *Jan.*, 42, 44
failure, fulminant, effect of PGI_2 infusion on oxygen delivery and uptake index in, *Apr.*, 257
metastases due to small cell lung cancer, *Dec.*, 789–790
in porphyria cutanea tarda, *Jan.*, 39
transplantation in protoporphyria, *Jan.*, 45
L-P ratio: in lactic acidosis, *Apr.*, 273–274
Lung
(*See also* Pulmonary)
cancer (*see* Cancer, lung)
scans, ventilation perfusion, in pulmonary hypertension, *Oct.*, 678
transplant in primary pulmonary hypertension, *Oct.*, 705
Luteinizing hormone-releasing hormone: in acute intermittent porphyria, *Jan.*, 34
Lymphoblastic lymphoma, *Sept.*, 639–642
Lymphocyte maturation: normal, *Sept.*, 608
Lymphoma
aggressive
chemotherapy of (*see* Chemotherapy, of lymphomas, aggressive)
classification of, *Sept.*, 614
AIDS-related, *Sept.*, 636–638
Burkitt's, *Sept.*, 633–636
staging of, *Sept.*, 635
indolent
chemotherapy of, *Sept.*, 620–624
classification of *Sept.*, 614
lymphoblastic, *Sept.*, 639–642
malignant
chemotherapy of (*see* Chemotherapy, of lymphomas, malignant)
of T cell origin, *Sept.*, 638–646
non-Hodgkin's, *Sept.*, 607–650
biology of, *Sept.*, 607–612
classification of, *Sept.*, 612–615

Lymphoma *(cont.)*
epidemiology of, *Sept.*, 615
etiology of, *Sept.*, 615
management, recent advances in, *Sept.*, 607–650
natural history of, *Sept.*, 615–616
radiation therapy of, *Sept.*, 619
staging of, *Sept.*, 616–618
staging of, Ann Arbor, *Sept.*, 617
staging of, recommended work-up, *Sept.*, 618
treatment of, *Sept.*, 619–633
T cell leukemia/lymphoma, retrovirus associated adult, *Sept.*, 644–646

M

Macrocytic anemia: in cancer, *Nov.*, 744
Magnesium
heat stress and, *May*, 326
levels, and diuretics, *Mar.*, 191
Magnetic resonance imaging
in hypertension, chronic thromboembolic, *Oct.*, 678
thyroid, *Aug.*, 574
Malignancy (*see* Cancer)
Marrow
involvement in malignancy, *Nov.*, 743–744
metastases from small cell lung cancer, *Dec.*, 790–791
Meal frequency: in obesity, *July*, 493
Medical history: in hypertension diagnosis, *Mar.*, 166
Megaloblastic anemia: in malignancy, *Nov.*, 745
Menarch onset: in obesity, *July*, 482
Menstrual disorders: and obesity, *July*, 482
Metabolic
changes in obesity, *July*, 481–482
defect
in coproporphyria, hereditary, *Jan.*, 35
in porphyria, acute intermittent, *Jan.*, 30–31
in porphyria cutanea tarda, *Jan.*, 39–40
in porphyria, erythropoietic, *Jan.*, 47
in porphyria, variegate, *Jan.*, 36
in protoporphyria, *Jan.*, 43–45
rate, resting, and obesity, *July*, 472–473
Metabolism errors: inborn, causing lactic acidosis, *Apr.*, 266–268
Metaproterenol: in chronic obstructive pulmonary disease, *Oct.*, 698
Metastases from small cell lung cancer
central nervous system, *Dec.*, 791–792
liver, *Dec.*, 789–790
marrow, *Dec.*, 790–791
Metformin: causing lactic acidosis, *Apr.*, 262
Methanol: causing lactic acidosis, *Apr.*, 263
Methylcellulose: in obesity, *July*, 518
Methyldopa: in hypertension, *Mar.*, 208–209
α-Methylparatyrosine: in pheochromocytoma, *Mar.*, 221
Metoproterenol: causing lactic acidosis, *Apr.*, 265
Microangiopathic hemolytic anemia: in malignancy, *Nov.*, 748–750
Microscopy: electron, in small cell lung cancer, *Dec.*, 785
Microsomes: thyroid, antibodies to, *Aug.*, 574–576
Microvascular disease: causing acute renal failure, *Feb.*, 83–84
Milia: on hand in porphyria cutanea tarda, *Jan.*, 38
Miliaria: and heat stroke, *May*, 337
Mineralocorticoid excess: syndromes of, *Mar.*, 164
Minoxidil: in hypertension, *Mar.*, 212–213
Mitochondrial oxidative phosphorylation defects: causing lactic acidosis, *Apr.*, 267

Mitomycin C: causing hemolytic-uremic syndrome, *Nov.*, 750–751
Mitral valve prolapse: causing sudden death, *June*, 396
Molecular genetic analysis: of non-Hodgkin's lymphomas, *Sept.*, 610–612
Monitoring (*see* Ambulatory monitoring)
Monoclonal antibody
  in lung cancer, small cell, *Dec.*, 811
  therapy in mycosis fungoides and Sézary syndrome, *Sept.*, 644
Mortality
  of heat stroke, in elderly, *May*, 358
  of hyperthermia, malignant, *May*, 355
  ratio and body mass index, *July*, 477
  sudden death (*see* Sudden death)
MRI (*see* Magnetic resonance imaging)
Mucilage: in obesity, *July*, 518
Muscle blood flow: and work in heat, *May*, 316
Mycosis fungoides, *Sept.*, 642–644
Myeloma: multiple, acute renal failure in, *Feb.*, 114–115
Myelopathy patients: hyperthermia with sepsis in, *May*, 353
Myocardial
  damage in heat stroke, *May*, 347
  disease, primary, and sudden death, *June*, 396
  function, effect of thiamine deficiency on, *Apr.*, 262
  infarction
    arrhythmias after, prognostic value of, *June*, 407
    in heat stroke, *May*, 347
    risk assessment after (*see* Sudden death, cardiac, risk assessment after myocardial infarction)
    risk management after (*see* Sudden death, cardiac, risk management after myocardial infarction)
    sudden death due to, *June*, 395–396
  Myoglobinuric acute renal failure, *Feb.*, 110–112

N

Na (*see* Sodium)
Natriuretic
  factor, atrial (*see* Atrial natriuretic, factor)
  peptides, atrial, and control of blood pressure and volume, *Mar.*, 159
Neck veins: in cor pulmonale diagnosis, *Oct.*, 688–689
Necrosis
  narrow, in malignancy, *Nov.*, 744
  renal cortical, *Feb.*, 109
  tubular (*see* Tubular necrosis, acute)
Neoplastic disorders: associated with acute renal failure, *Feb.*, 114–116
Nephritis: acute interstitial, *Feb.*, 96
Nephropathy: acute uric acid, causing acute renal failure, *Feb.*, 116
Nephrotoxic injuries; avoidance in acute renal failure, *Feb.*, 125–126
Nervous system (*see* Central nervous system)
Neuroleptic malignant syndrome, *May*, 356–357
Neurological
  disorders, paraneoplastic, and small cell lung cancer, *Dec.*, 797
  dysfunction in porphyria, pathogenesis of, *Jan.*, 21–26
    schematic of, *Jan.*, 24
Neuromyopathies: and small cell lung cancer, *Dec.*, 797–799
Neutropenia
  after captopril, *Mar.*, 200
  in malignancy, *Nov.*, 754
Nickel exposure: and lung cancer, *Dec.*, 781

Nifedipine
in hypertension, *Mar.*, 196
pulmonary, primary, *Oct.*, 704
in hypertensive crisis, *Mar.*, 215
in pulmonary disease, chronic obstructive, *Oct.*, 702
Nitrogen: in diet for obesity, *July*, 492–493
Nitrogenous waste
tubular handling of, *Feb.*, 80
urinary elimination of
four major steps in, *Feb.*, 72
glomerular filtration fraction related to salt and water reabsorption in, *Feb.*, 76–80
glomerular filtration rate and, *Feb.*, 75–76, 77
physiology of, *Feb.*, 74–80
renal blood flow and, *Feb.*, 74–75, 76
Nitroglycerin: in hypertensive crisis, *Mar.*, 216
Nitroprusside
in hypertensive crisis, *Mar.*, 215–216
lactic acidosis due to, *Apr.*, 265
Nodule: solitary thyroid, schema for investigation of, *Aug.*, 590
Norepinephrine: and work in heat, *May*, 317, 320–321
Nutrient imbalance: and obesity, *July*, 470–475
Nutrition
considerations in acute renal failure, *Feb.*, 124–125
group selections for weight loss, *July*, 500
label, *July*, 494

O

Obesity, *July*, 461–537
adipose tissue and, *July*, 475–476
in Ahlstrom's syndrome, *July*, 484
in Bardet-Biedl syndrome, *July*, 484
benzocaine in, *July*, 518
beta-adrenergic agonists for, *July*, 518
cardiovascular system function and, *July*, 478–480
in Carpenter's syndrome, *July*, 484
classification of, *July*, 485–487
by age of onset, *July*, 487
anatomic, *July*, 486
etiologic, *July*, 486–487
clinical types of, *July*, 483–487
in Cohen's syndrome, *July*, 484
diabetes mellitus and, *July*, 480–481
diet for, *July*, 491–505
basic considerations, *July*, 491–493
conventional, *July*, 498–504
estimating caloric need, *July*, 493–498
1,000-calorie Menumax food servings, *July*, 501
very low calorie, *July*, 504–505
very low calorie, comparison to behavior modification, *July*, 526
dinitrophenol in, *July*, 518
diphenylhydantoin for, *July*, 516
drugs for, *July*, 511–520
affecting gastrointestinal tract, *July*, 518–519
appetite-suppressing (*see* Appetite-suppressing drugs)
thermogenic, *July*, 517–518
endocrine changes in, *July*, 481–482
energy expenditure and, *July*, 471–472
enzyme inhibitors in, *July*, 519
ephedrine for, *July*, 517
exercise for, *July*, 509–510
fat mobilization in, regional, *July*, 520
fiber therapy in, *July*, 518–519
food intake and, *July*, 470–471
gallbladder disease and, *July*, 481
gastric bubble for, *July*, 520
gastric bypass in, *July*, 522
comparison with jejunoileal bypass, *July*, 524
gastric operations in, *July*, 522–524

gastrointestinal procedures in, *July*, 521–522
genetic factors in, *July*, 483–485
gonadotropin in, human chorionic, *July*, 519–520
growth hormone therapy in, *July*, 518
health risks and, *July*, 476–482
heat tolerance and, *May*, 336
jaw wiring for, *July*, 520–521
  comparison to behavioral treatment, *July*, 527
jejunoileal bypass in, *July*, 522, 524–525
comparison with gastric bypass, *July*, 524
lipectomy in, suction-assisted, *July*, 521
liposuction in, *July*, 521
metabolic changes in, *July*, 481–482
metabolic rate and, resting, *July*, 472–473
nutrient imbalance and, *July*, 470–475
opioid antagonists for, *July*, 517
organ function and, *July*, 478–482
pathogenesis of, *July*, 470–476
phenylpropanolamine for, *July*, 515–516
physical activity in, *July*, 473–474
analysis of, *July*, 497
  energy expenditure related to, *July*, 496
  levels of, *July*, 495
  monitor for, *July*, 496
in Prader-Willi syndrome, *July*, 484
prevalence of, *July*, 467–470
pulmonary function and, *July*, 481
starvation in, *July*, 505
sucrose polyester in, *July*, 519
sudden cardiac death and, *June*, 394
thermogenic response to food in, *July*, 474–475
thyroid hormone therapy in, *July*, 517
treatment of, *July*, 491–525
  approaches to, *July*, 487–491
  behavioral (*see* Behavioral, treatment of obesity)
  comparative effectiveness of, *July*, 527–528
  costs, *July*, 525, 528
  efficacy of, *July*, 525
  goals of, *July*, 487–488
  invasive, *July*, 520–525
  maintenance, *July*, 528
  psychoanalysis for, *July*, 509
  realities of, *July*, 487–488
  risk of, *July*, 525
  risk-benefit assessment of, *July*, 490–491
  risk evaluation and, *July*, 488–490
  safety of, *July*, 526
  vagotomy in, *July*, 521
  weight loss in (*see* Weight, loss in obesity)
Olestra: in obesity, *July*, 519
Opioid antagonists: for obesity, *July*, 517
Oral contraceptive-induced hypertension, *Mar.*, 169–170
Organ function: and obesity, *July*, 478–482
Osmolality: urinary, in acute renal failure, *Feb.*, 99, 101
Oxidative phosphorylation defects: causing lactic acidosis, *Apr.*, 267
Oxygen
  delivery
    in hepatic failure, fulminant, effect of PGI_2 on, *Apr.*, 257
    in respiratory failure, acute, *Apr.*, 272
  flux test in lactic acidosis, *Apr.*, 270
  supply dependency
    pathological, *Apr.*, 273
    physiological, *Apr.*, 270, 273
  therapy in chronic obstructive pulmonary disease, *Oct.*, 698–700
  in acute exacerbations, *Oct.*, 698–699
  long term, selection criteria for, *Oct.*, 700

Oxygen *(cont.)*
stable, *Oct.*, 699–700
uptake
in hepatic failure, fulminant, effect of PGI_2 on, *Apr.*, 257
in respiratory failure, acute, *Apr.*, 272

P

Pacing: for ventricular tachycardia, *June*, 431–432
Palpation: thyroid, *Aug.*, 551–552
Palpitation: of cardiac impulse in diagnosis of cor pulmonale, *Oct.*, 689–690
Pancreas cancer: and venous thrombosis, *Nov.*, 757
Pancreatitis: in heat stroke, *May*, 349
Panhematin: in acute intermittent porphyria, *Jan.*, 32
Paraneoplastic
neurological disorders and small cell lung cancer, *Dec.*, 797
syndromes and small cell lung cancer, *Dec.*, 792–800
Peptides: atrial natriuretic, and control of blood pressure and volume, *Mar.*, 159
pH: urine, and heat stress, *May*, 324–325
Pharmacologic
effects of appetite-suppressing drugs, *July*, 511
screening in renovascular hypertension, *Mar.*, 171
treatment of hypertension, *Mar.*, 186–188
stepped-care program, *Mar.*, 187
Phenformin: causing lactic acidosis, *Apr.*, 262–263
Phenothiazines: causing neuroleptic malignant syndrome, *May*, 356
Phenylpropanolamine: for obesity, *July*, 515–516
Phenytoin: for obesity, *July*, 516
Pheochromocytoma
diagnosis of, *Mar.*, 175–177
humoral control of, *Mar.*, 164–165
lactic acidosis in, *Apr.*, 261
signs and symptoms of, *Mar.*, 175
storm, and heat stroke, *May*, 354–355
treatment of, *Mar.*, 220–221
Phlebotomy: in chronic obstructive pulmonary disease, *Oct.*, 696
Phosphorus
balance management in acute renal failure, *Feb.*, 122
heat stress and, *May*, 326
Pickwickian syndrome: and obesity, *July*, 481
Pituitary thyrotroph cell: and TSH release, *Aug.*, 558
Plasma
exchange in chemotherapy associated hemolytic-uremic syndrome, *Nov.*, 750
urinary to plasma creatinine ratio in acute renal failure, *Feb.*, 101
Platelet abnormalities: in malignancy, *Nov.*, 754–755
Poisoning
acetaminophen, causing lactic acidosis, *Apr.*, 265
carbon monoxide, causing lactic acidosis, *Apr.*, 255
epinephrine, lactic acidosis in, *Apr.*, 261
isoniazid, causing lactic acidosis, *Apr.*, 266
salicylate, causing lactic acidosis, *Apr.*, 264–265
Polycythemia
in malignancy, *Nov.*, 751–753
in pulmonary disease, chronic obstructive, treatment of, *Oct.*, 696
Polyuria: and heat stress, *May*, 328
Porphobilinogen deaminase deficiency in porphyria, *Jan.*, 19
acute intermittent, *Jan.*, 30–31
Porphyria, *Jan.*, 13–54
biochemical abnormalities in, *Jan.*, 14–20

clinical manifestations, pathogenesis of, *Jan.*, 21–28
cutanea tarda, *Jan.*, 37–41
estrogen in, *Jan.*, 40
ethanol in, *Jan.*, 40
features of, clinical and biochemical, *Jan.*, 37–39
genetics of, *Jan.*, 37
incidence of, *Jan.*, 37
iron overload causing, *Jan.*, 40
management of, *Jan.*, 40–41
metabolic defect in, *Jan.*, 39–40
cutaneous lesions, pathogenesis of, *Jan.*, 26–28
enzyme defects in, *Jan.*, 16, 19–20
erythropoietic, congenital, *Jan.*, 46–47
features of, clinical and biochemical, *Jan.*, 46
genetics of, *Jan.*, 46
incidence of, *Jan.*, 46
metabolic defect in, *Jan.*, 47
treatment of, *Jan.*, 47
heme biosynthesis in, *Jan.*, 14–18
pathway, *Jan.*, 16
hepatic, acute, *Jan.*, 29
δ-aminolevulinic acid dehydrase deficiency causing, *Jan.*, 36–37
chemicals in, *Jan.*, 25
drugs in, *Jan.*, 25
hepatoerythropoietic, *Jan.*, 41–42
intermittent, acute, *Jan.*, 29–34
features of, biochemical, *Jan.*, 29–30
features of, clinical, *Jan.*, 21, 29–30
genetics of, *Jan.*, 29
incidence of, *Jan.*, 29
metabolic defect in, *Jan.*, 30–31
pathology of, *Jan.*, 31–32
prevention of, *Jan.*, 34
prognosis of, *Jan.*, 34
treatment of, *Jan.*, 32–34
neurologic dysfunction in, pathogenesis of, *Jan.*, 21–26
schematic of, *Jan.*, 24
porphyrin and porphyrin precursor excretion patterns in, *Jan.*, 18–19
variegate, *Jan.*, 36
features of, clinical and biochemical, *Jan.*, 36
genetics of, *Jan.*, 36
incidence of, *Jan.*, 36
metabolic defect in, *Jan.*, 36
treatment of, *Jan.*, 36
Porphyrin
chemical and biologic properties of, *Jan.*, 16
excretion, patterns of, *Jan.*, 18–19
precursor excretion, patterns of, *Jan.*, 18–19
structure of, *Jan.*, 15
tissue injury produced by, in presence of light energy and molecular oxygen, *Jan.*, 27
Porphyrinogens: chemical and biologic properties of, *Jan.*, 16
Porphyrinuria: secondary, *Jan.*, 48–49
Postoperative acute renal failure, *Feb.*, 116
Potassium
deficiency, implications in heat stroke, *May*, 337–339
heat stress and, *May*, 325–326, 327–328
metabolism management in acute renal failure, *Feb.*, 121
supplementation in hypertension, *Mar.*, 182–183
Prader-Willi syndrome: obesity in, *July*, 484
Prazosin
in hypertension, *Mar.*, 210
in pulmonary disease, chronic obstructive, *Oct.*, 701
Precordium inspection: in diagnosis of cor pulmonale, *Oct.*, 689
Pregnancy: hypertension in, *Mar.*, 153
Prerenal
acute renal failure, pathophysiology of, *Feb*, 81–83
states related to acute tubular necrosis, *Feb.*, 94–95
Proarrhythmia: due to antiarrhythmic drug therapy, *June*, 422–423

Propylene glycol: causing lactic acidosis, *Apr.*, 266
Prostacyclin
in hypertension, primary pulmonary, *Oct.*, 704–705
infusion in fulminant liver failure, *Apr.*, 257
Prostaglandin
control of blood pressure and volume and, *Mar.*, 157–158
interaction with kallikrein-kinin and renin-angiotensin systems, *Mar.*, 158
Protein
A hemoperfusion in chemotherapy associated hemolytic-uremic syndrome, *Nov.*, 750
thyroid-binding (*see* Thyroid, -binding proteins)
proteinuria: due to captopril, *Mar.*, 200
Protoporphyria, *Jan.*, 42–45
features of, clinical and biochemical, *Jan.*, 42–43
genetics of, *Jan.*, 42
hepatic disease in, *Jan.*, 42, 44
incidence of, *Jan.*, 42
metabolic defect in, *Jan.*, 43–45
treatment of, *Jan.*, 45
Protoporphyrinogen oxidase deficiency: in variegate porphyria, *Jan.*, 36
Psychoanalysis: for treatment of obesity, *July*, 509
Psychotic behavior: preceding heat stroke, *May*, 344
Pulmonary
(*See also* Lung)
angiography in cor pulmonale, *Oct.*, 678
artery enlargement on chest x-rays, *Oct.*, 684, 687
cardiopulmonary resuscitation, *June*, 432–434
disease, chronic obstructive
(*See also* Cor pulmonale)
alpha-adrenergic blockade in, *Oct.*, 701
angiotensin-converting enzyme inhibitors in, *Oct.*, 701
anticholinergic agents in, *Oct.*, 697–698
atrial natriuretic factor in, *Oct.*, 695–696
beta-adrenergic agonists in, *Oct.*, 697, 701
bronchodilators in, *Oct.*, 696–698
calcium channel blockers in, *Oct.*, 702
corticosteroids in, *Oct.*, 694
diuretics in, *Oct.*, 695–696
echocardiography in, *Oct.*, 679–680
exacerbations of, acute infective, treatment of, *Oct.*, 693
hemodynamics in, *Oct.*, 670
hydralazine in, *Oct.*, 701–702
oxygen therapy in (*see* Oxygen, therapy in chronic obstructive pulmonary disease)
polycythemia and phlebotomy in, *Oct.*, 696
theophylline compounds in, *Oct.*, 696–697
treatment of, *Oct.*, 693–702
vaccine protection in, *Oct.*, 694
vasodilators in, *Oct.*, 701–702
function and obesity, *July*, 481
hypertension (*see* Hypertension, pulmonary)
thromboendarterectomy in thromboembolic pulmonary hypertension, *Oct.*, 707
vascular bed in cor pulmonale, *Oct.*, 667–669
vasodilation, effect on pressure volume relationship in right ventricle, *Oct.*, 668
PVC hypothesis of sudden death, *June*, 397–398
comparison with substrate hypothesis, *June*, 399
Pyelogram: in renovascular hypertension, *Mar.*, 170
Pyruvate
carboxylase deficiency causing lactic acidosis, *Apr.*, 266
dehydrogenase deficiency causing lactic acidosis, *Apr.*, 267

Pyruvate *(cont.)*
oxidation defects causing lactic acidosis, *Apr.*, 266–267

Q

Quetelet index (*see* Body, mass index)

R

Race
hypertension awareness, treatment, and control status by, *Mar.*, 147
obesity and, *July*, 469
Radiation
definition of, *May*, 314
diagnostic
in cor pulmonale, *Oct.*, 677–678, 684, 687, 688
thyroid, *Aug.*, 574
ionizing, causing small cell lung cancer, *Dec.*, 780–781
therapy
brain, and dementia in small cell lung cancer, *Dec.*, 799–800
of lung cancer, small cell, *Dec.*, 814
of lung cancer, small cell, combined with chemotherapy, *Dec.*, 809–810
of lymphoma, non-Hodgkin's, *Sept.*, 619
Radioactive iodine thyroid uptake test, *Aug.*, 571–572
Radiocontrast-media-induced acute renal failure, *Feb.*, 113
contrasted with atheroembolic-induced acute renal failure, *Feb.*, 111
Radiography (*see* Radiation, diagnostic)
Radioimmunoassay
total serum T_4 and T_3 by, *Aug.*, 562
total serum T_3 by, *Aug.*, 562–563
Radiotherapy (*see* Radiation, therapy)
Rash: skin, due to captopril, *Mar.*, 200
Red cell
anemia of increased red cell consumption in cancer, *Nov.*, 745–751
aplasia in malignancy, *Nov.*, 742
transfusion (*see* Transfusion, red cell)
Renal
(*See also* Kidney)
artery stenosis, arteriographic findings in, *Mar.*, 171
vessels
large, occlusion, causing acute renal failure, *Feb.*, 83
microvascular disease causing acute renal failure, *Feb.*, 83–84
renovascular hypertension (*see* Hypertension, renovascular)
Renin
-angiotensin system
control of blood pressure and volume and, *Mar.*, 155–156
interaction with kallikrein-kinin and prostaglandin systems, *Mar.*, 158
work in heat and, *May*, 319–320
release, control of, and juxtaglomerular apparatus, *Mar.*, 156
Renogram: captopril, in renovascular hypertension, *Mar.*, 171
Renovascular hypertension (*see* Hypertension, renovascular)
Resin T_3 uptake test, *Aug.*, 563
Respiratory
alkalosis in heat stroke, *May*, 352
failure, acute, oxygen uptake and oxygen delivery in, *Apr.*, 272
Resuscitation: cardiopulmonary, *June*, 432–434
Reticulocyte maturation index: for different hematocrits, *Nov.*, 733
Reticulum: sarcoplasmic, and malignant hyperthermia, *May*, 355

Retinol: and lung cancer, *Dec.*, 782
Retrosternal space filling: on chest x-ray, *Oct.*, 684
Retrovirus associated adult T cell leukemia/lymphoma, *Sept.*, 644–646
Rhabdomyolysis in heat stroke, *May*, 349
  in men, *May*, 338
  treatment of, *May*, 361
  in women, *May*, 346
RIA (*see* Radioimmunoassay)
Ritodrine: causing lactic acidosis, *Apr.*, 265
RO 16-8714: for obesity, *July*, 518

S

Salicylate poisoning: causing lactic acidosis, *Apr.*, 264–265
Salt
  (*See also* Sodium)
  depletion causing heat exhaustion, *May*, 333–334
  reabsorption related to filtration fraction in elimination of nitrogenous waste, *Feb.*, 76–80
Sarcoplasmic reticulum: and malignant hyperthermia, *May*, 355
Scintigraphy: in thyroid cancer, *Aug.*, 590–591
Scopinaro procedures: in obesity, *July*, 525
Self-help programs: for obesity, *July*, 508
Seizure management: in acute intermittent porphyria, *Jan.*, 34
Sepsis
  B state, *Apr.*, 260
  hyperthermia in myelopathy patients and, *May*, 353
  lactic acidosis in, *Apr.*, 259–261
  renal failure and, acute, *Feb.*, 108
Septic shock: causing lactic acidosis, *Apr.*, 255
Serotonin neurotransmitters: appetite-suppressing drugs acting on, *July*, 515
Sex
  hypertension awareness, treatment and control status by, *Mar.*, 147
  obesity and, *July*, 469
Sézary syndrome, *Sept.*, 642–644
Shock: causing lactic acidosis, *Apr.*, 255
Shoshin beriberi: lactic acidosis in, *Apr.*, 261–262
Skin
  lesions of porphyria, pathogenesis of, *Jan.*, 26–28
  rash due to captopril, *Mar.*, 200
Skinfold thickness
  for assessing obesity, *July*, 462
  heart disease and, *July*, 479
Smear: peripheral, in anemia in malignancy, *Nov.*, 735
Smoking
  cessation in hypertension, *Mar.*, 185
  lung cancer due to, small cell, *Dec.*, 780–781
  sudden cardiac death and, *June*, 392–393
Socioeconomic status: and obesity, *July*, 468–469
Sodium
  (*See also* Salt)
  concentration, urinary, in acute renal failure, *Feb.*, 99
  fractional excretion, in acute renal failure, *Feb.*, 101–103
  handling, renal, and control of blood pressure and volume, *Mar.*, 159–160
  ion concentration, sweat, related to sweat rate, *May*, 330
  nitroprusside (*see* Nitroprusside)
  restriction, dietary, in hypertension, *Mar.*, 180–181
Solute diuresis: in prevention of acute tubular necrosis, *Feb.*, 117–119
Sorbitol: causing lactic acidosis, *Apr.*, 263–264
Spironolactone: in primary aldosteronism, *Mar.*, 220

Splanchnic blood flow: and work in heat, *May*, 317
Splenectomy
for hypersplenism in malignancy, *Nov.*, 746
in porphyria, congenital erythropoietic, *Jan.*, 47
Startling forces: in glomerular filtration rate, *Feb.*, 75–76, 77
Starvation: in obesity, *July*, 505
Stenosis
aortic, causing sudden death, *June*, 396
renal artery, arteriographic findings in, *Mar.*, 171
Steroid reductase deficiency: in acute intermittent porphyria, *Jan.*, 31
Streptococcus pneumoniae vaccine: in chronic obstructive pulmonary disease, *Oct.*, 694
Stress
heat (*see* Heat, stress)
hyperlactatemia, *Apr.*, 261
Stroke
heat (*see* Heat, stroke)
volume during work in heat, *May*, 319
Substrate hypothesis of sudden death (*see* Sudden death, cardiac, substrate hypothesis of)
Sucrose polyester: in obesity, *July*, 519
Suction-assisted lipectomy: in obesity, *July*, 521
Sudden death
cardiac *(see below)*
definition of, *June*, 391–392
etiology of, *June*, 392
cardiac, *June*, 393
noncardiovascular, *June*, 394
Sudden death, cardiac, *June*, 391–445
causes of, *June*, 393
epidemiology of, *June*, 392–395
pathogenesis, *June*, 396–406
mechanisms of, *June*, 396–397
theories of, *June*, 397–406
pathology of, *June*, 395–396
PVC hypothesis of, *June*, 397–398
comparison with substrate hypothesis, *June*, 399
risk assessment, *June*, 406–417
risk assessment after myocardial infarction, *June*, 407–415
ambulatory monitoring for, *June*, 407–410
combinations and comparisons, *June*, 414–415
electrocardiogram for, signal-averaged, *June*, 410–412
electrophysiological studies for, *June*, 412–414
left ventricular dysfunction markers, *June*, 410
risk assessment after sustained ventricular tachycardia or sudden death, *June*, 415–417
ambulatory monitoring for, *June*, 415–416
electrophysiologic study for, *June*, 416–417
left ventricular dysfunction markers, *June*, 416
risk management, *June*, 417–434
risk management after myocardial infarction, *June*, 418–424
antiarrhythmic drugs for (*see* Antiarrhythmic drugs, in prevention of sudden death after myocardial infarction)
anti-ischemic therapy for, *June*, 423–425
risk management after sustained ventricular tachycardia or sudden death, *June*, 425–434
antiarrhythmic drugs for (*see* Antiarrhythmic drugs, in prevention of sudden death after sustained ventricular tachycardia or sudden death)
cardiopulmonary resuscitation and defibrillation, *June*, 432–434
catheter ablation in, *June*, 431–432
nonmedical therapy, *June*, 431–434
pacing in, *June*, 431–432

Sudden death, cardiac, *June (cont.)*
surgery in, *June*, 431–432
substrate hypothesis of, *June*, 398–406
anatomy of substrate, *June*, 404–405
comparison with PVC hypothesis, *June*, 399
electrocardiogram in, signal-averaged, *June*, 401, 402–403
electrophysiological studies, *June*, 401, 404
electrophysiology of substrate, *June*, 399–404
endocardial mapping in, *June*, 400–401
variability of substrate, *June*, 405–506
Suppressive therapy: in thyroid cancer, thyroid function tests after, *Aug.*, 589–590
Sweat
composition, and work in heat, *May*, 321–324
production impairment, and heat stroke, *May*, 337
sodium ion concentration related to sweat rate, *May*, 330
volume, and work in heat, *May*, 321–324
Sympatholytic agents: in hypertension, *Mar.*, 202–206
Syncope: heat, *May*, 329

T

T_3 (*see* Triiodothyronine)
T_4 (*see* Thyroxine)
Tachycardia, ventricular, sustained, sudden death after
risk assessment for (*see* Sudden death, cardiac, risk assessment after sustained ventricular tachycardia or sudden death)
risk management for (*see* Sudden death, cardiac, risk management after sustained ventricular tachycardia or sudden death)
Taste disturbances: due to captopril, *Mar.*, 200
T cell
leukemia/lymphoma, retrovirus associated adult, *Sept.*, 644–646
origin of malignant lymphomas, *Sept.*, 638–646
Teniposide: in small cell lung cancer, *Dec.*, 807
Terazosin: in hypertension, *Mar.*, 211
Terbutaline
lactic acidosis due to, *Apr.*, 265
in pulmonary disease, chronic obstructive, *Oct.*, 701
Testosterone: and obesity, *July*, 482
Tetany: heat, *May*, 329
Tetrahydrolipostatin: in obesity, *July*, 519
Theophylline
compounds in chronic obstructive pulmonary disease, *Oct.*, 696–697
in prevention of acute tubular necrosis, *Feb.*, 119
Thermogenic
drugs for obesity, *July*, 517–518
effects of food, *July*, 474–475
Thermoregulation: in heat, *May*, 313–314
Thiamine
deficiency, lactic acidosis in, *Apr.*, 261–262
therapy in lactic acidosis, *Apr.*, 283
Thioxanthenes: causing neuroleptic malignant syndrome, *May*, 356
Thrombocytopenia: in malignancy, *Nov.*, 755
Thrombocytosis: in malignancy, *Nov.*, 754–755
Thromboembolic pulmonary hypertension (*see* Hypertension, pulmonary, thromboembolic)
Thromboendarterectomy: in thromboembolic pulmonary hypertension, *Oct.*, 707

Thrombophlebitis: in malignancy, *Nov.*, 757
Thrombosis: in malignancy, *Nov.*, 756
Thrombotic
coronary occlusion, and sudden death, *June*, 395
endocarditis, nonbacterial, in cancer, *Nov.*, 757–758
Thromboxane-synthesis inhibitors: in prevention of acute tubular necrosis, *Feb.*, 119
Thymoma: red cell aplasia in, *Nov.*, 742
Thyroglobulin, *Aug.*, 570–571
antibodies to, *Aug.*, 574–576
levels, serum, causes of elevation or depression of, *Aug.*, 570
measurements, *Aug.*, 570–571
Thyroid
anatomy, *Aug.*, 551
antibodies, *Aug.*, 574–577
-binding globulin, *Aug.*, 557
effects of drugs and pathophysiological states on, *Aug.*, 555
-binding proteins
serum, *Aug.*, 554
T_4 and T_3 binding to, drugs interfering with, *Aug.*, 556
cancer (*see* Cancer, thyroid)
disorders, incidence of antibodies to thyroglobulin and thyroid microsomes in, *Aug.*, 575
dysfunction, screening of well individuals for, *Aug.*, 580–581
adults, *Aug.*, 580–581
infants, *Aug.*, 580
function tests, *Aug.*, 551–595
dynamic, *Aug.*, 577–580
in exclusion of thyrotoxicosis, *Aug.*, 582
in hyperthyroidism diagnosis, *Aug.*, 581–583
in hyperthyroidism diagnosis, differential, *Aug.*, 582–583
in hypothyroidism diagnosis, *Aug.*, 583–585
in hypothyroidism diagnosis, in symptomatic ambulatory patient, *Aug.*, 585
interpretation of, *Aug.*, 551–595
in nonthyroidal illness, *Aug.*, 586–588
in screening of asymptomatic patient for hypothyroidism, *Aug.*, 584–585
in screening of symptomatic ambulatory patient for hypothyroidism, *Aug.*, 584
in screening of well individuals for thyroid dysfunction, *Aug.*, 580–581
in thyroid cancer, *Aug.*, 589–592
in thyroid cancer, after suppressive therapy, *Aug.*, 589–590
in thyroiditis (*see* Thyroiditis, thyroid function tests in)
in thyrotoxicosis, mild or equivocal, *Aug.*, 582
in thyrotoxicosis, overt, *Aug.*, 581
use of, *Aug.*, 580–581
hormone
binding ratio, *Aug.*, 563–565
disposal of T_4 and T_3, *Aug.*, 555–557
feedback regulation of, *Aug.*, 557–559
iodine metabolism and, *Aug.*, 553–554
measurement of, *Aug.*, 559–571
pathophysiology, *Aug.*, 552–559
therapy in obesity, *July*, 517
transport of T_4 and T_3, *Aug.*, 554–555
imaging, *Aug.*, 572–573
indications for, *Aug.*, 572
magnetic resonance, *Aug.*, 574
x-ray, *Aug.*, 574
inspection, *Aug.*, 551
microsomes, antibodies to, *Aug.*, 574–576
nodule, solitary, schema for investigation of, *Aug.*, 590
palpation, *Aug.*, 551–552
-stimulating antibodies, *Aug.*, 576–577

Thyroid *(cont.)*
-stimulating hormone, *Aug.*, 577–578
release, and pituitary thyrotroph cell, *Aug.*, 558
storm, and heat stroke, *May*, 354
tomography of, computed, *Aug.*, 574
ultrasonography, *Aug.*, 573
in cancer, *Aug.*, 591
uptake tests, *Aug.*, 571–574
radioactive iodine, *Aug.*, 571–572
Thyroiditis, thyroid function tests in *Aug.*, 585–586
acute suppurative, *Aug.*, 585
chronic, *Aug.*, 586
subacute, *Aug.*, 585–586
Thyrotoxicosis
exclusion of, thyroid function tests for, *Aug.*, 582
mild or equivocal, thyroid function tests in, *Aug.*, 582
overt, thyroid function tests in, *Aug.*, 581
Thyrotroph cell: pituitary, and TSH release, *Aug.*, 558
Thyrotropin, *Aug.*, 567–568
measurements, *Aug.*, 567–568
in nonthyroidal illness, *Aug.*, 588
-releasing hormone, *Aug.*, 569–570
challenge tests, *Aug.*, 578–580
ultrasensitive, *Aug.*, 568–569
Thyroxine
binding to thyroid binding proteins, drugs interfering with, *Aug.*, 556
conversion to triiodothyronine, decreased peripheral, drugs and conditions associated with, *Aug.*, 556
dialyzable, *Aug.*, 566–567
disposal of, *Aug.*, 555–557
free, *Aug.*, 566–567
index, *Aug.*, 565–566
by newer methods, *Aug.*, 567
obesity and, *July*, 481–482
pathways of degradation to form T_3, rT_3, and other inactive metabolites, *Aug.*, 557
total, *Aug.*, 559–562
assay methodology, *Aug.*, 559–562
total serum T_4 and T_3 by RIA, *Aug.*, 562
transport, and thyroid hormone, *Aug.*, 554–555
Tobacco: causing small cell lung cancer, *Dec.*, 780–781
Tomography, computed (*see* Computed tomography)
Torsade de pointes, *June*, 422
Toxins: causing lactic acidosis, *Apr.*, 262–268
Transfusion, red cell
in porphyria, congenital erythropoietic, *Jan.*, 47
in protoporphyria, *Jan.*, 45
Transplantation
heart-lung, in primary pulmonary hypertension, *Oct.*, 705
liver, in protoporphyria, *Jan.*, 45
Triiodothyronine
binding to thyroid binding proteins, drugs interfering with, *Aug.*, 556
dialyzable, *Aug.*, 566–567
disposal of, *Aug.*, 555–557
free
index, *Aug.*, 565–566
by newer methods, *Aug.*, 567
in nonthyroidal illness, *Aug.*, 587–588
obesity and, *July*, 481–482, 517
pathways of degradation of T_4 to form, *Aug.*, 557
reverse, pathways of degradation of T_4 to form, *Aug.*, 557
test, *Aug.*, 563
thyroxine conversion to, decreased peripheral, drugs and conditions associated with, *Aug.*, 556
total, *Aug.*, 559–562
assay methodology, *Aug.*, 559–562
total serum by RIA, *Aug.*, 562–563
total serum T_4 and T_3 by RIA, *Aug.*, 562
transport, and thyroid hormone, *Aug.*, 554–555

Tubular handling: of nitrogenous waste, *Feb.*, 80
Tubular necrosis, acute, *Feb.*, 84–95
clinical course of, *Feb.*, 104–106
creatinine in, serum, triphasic change in, *Feb.*, 106
hemodynamic changes in, *Feb.*, 89–91
pathogenic significance of, *Feb.*, 90
observations in experimental animal models, *Feb.*, 86–90
observations in humans, *Feb.*, 90–91
pathophysiology of, *Feb.*, 84–95
prerenal states related to, *Feb.*, 94–95
prevention of, *Feb.*, 117–119
solute diuresis in prevention of, *Feb.*, 117–119
syndromes, and acute renal failure, *Feb.*, 109
tubular mechanisms in, *Feb.*, 87–89
mechanisms of tubular cell injury, *Feb.*, 87–89
morphology of, *Feb.*, 87
volume expansion in prevention of, *Feb.*, 117–119

U

Ultrasound
abdominal, in renovascular hypertension, *Mar.*, 171
thyroid, *Aug.*, 573
in cancer, *Aug.*, 591
Uranium miners: lung cancer in, *Dec.*, 780–781
Urapadil: in chronic obstructive pulmonary disease, *Oct.*, 701
Uremia
chemotherapy-associated hemolytic-uremic syndrome, *Nov.*, 750–751
complications in acute renal failure, management of, *Feb.*, 122–123
Uric acid nephropathy: acute, causing acute renal failure, *Feb.*, 116
Urinalysis: routine, in acute renal failure, *Feb.*, 104
Urinary
"diagnostic indices" in acute renal failure, *Feb.*, 98–99, 100–101
elimination of nitrogenous waste (*see* Nitrogenous waste, urinary elimination of)
Na concentration in acute renal failure, *Feb.*, 99
osmolality in acute renal failure, *Feb.*, 99, 101
to plasma creatinine ratio in acute renal failure, *Feb.*, 101
Urine volumes: in acute renal failure, *Feb.*, 97
Uroporphyrinogen
decarboxylase deficiency in porphyria
cutanea tarda, *Jan.*, 39–40
hepatoerythropoietic, *Jan.*, 41–42
III cosynthase activity defect in congenital erythropoietic porphyria, *Jan.*, 47

V

Vaccine protection: against *S. pneumoniae* or influenza in chronic obstructive pulmonary disease, *Oct.*, 694
Vagotomy: in obesity, *July*, 521
Valve: mitral, prolapse, causing sudden death, *June*, 396
Vasodilation: pulmonary, effect on pressure volume relationship in right ventricle, *Oct.*, 668
Vasodilators
in hypertension, *Mar.*, 204–205, 212–213
pulmonary, primary, *Oct.*, 702–705

Vasodilators *(cont.)*
in pulmonary disease, chronic obstructive, *Oct.*, 701–702
Vasopressin, arginine
control of blood pressure and volume and, *Mar.*, 158–159
work in heat and, *May*, 321
Veins: neck, in cor pulmonale diagnosis, *Oct.*, 688–689
Ventilation-perfusion scans: in pulmonary hypertension, *Oct.*, 678
Ventricle
arrhythmias, diuretic-induced, *Mar.*, 189–190
left
dysfunction, in risk assessment for sudden death, after myocardial infarction, *June*, 410
dysfunction, in risk assessment for sudden death, after sustained ventricular tachycardia or sudden death, *June*, 416
function in chronic obstructive pulmonary disease, *Oct.*, 671
hypertrophy, and centrally acting drugs in hypertension, *Mar.*, 209–210
right
hypertrophy (*see* Hypertrophy, ventricular, right)
pressure volume relationship, effect of pulmonary vasodilation on, *Oct.*, 668
weight and size in chronic bronchitis and emphysema, *Oct.*, 664
tachycardia (*see* Tachycardia, ventricular)
Vessel(s)
bed, pulmonary, in cor pulmonale, *Oct.*, 667–669
cardiovascular (*see* Cardiovascular)
coronary, abnormalities, and sudden death, *June*, 396
renal (*see* Renal, vessels)
Vincristine in small cell lung cancer, *Dec.*, 803, 804–805
in alternating regimens, *Dec.*, 805
Vitamin A: and lung cancer, *Dec.*, 782
VM-26: in small cell lung cancer, *Dec.*, 807
Volume expansion: in prevention of acute tubular necrosis, *Feb.*, 117–119
von Gierke's disease: causing lactic acidosis, *Apr.*, 266
VP-16 in small cell lung cancer, *Dec.*, 804–805, 806
plus cisplatin, *Dec.*, 805, 807

W

Waist-to-hips ratio
nomogram for determining, *July*, 465
relation to risks for obesity, *July*, 480
Warfarin (*see* Coumadin)
Water
depletion causing heat exhaustion, *May*, 332–333
reabsorption related to filtration fraction in elimination of nitrogenous waste, *Feb.*, 76–80
Weight
energy expenditure related to, *July*, 496
loss in obesity
with behavior modification, *July*, 507
does it improve health? *July*, 482
effect of appetite-suppressing drugs on, *July*, 514
nutrition group selections for, *July*, 500
rate of, *July*, 525–526
with very low calorie diets, *July*, 505
metabolic rate and, *July*, 473
reduction for hypertension, *Mar.*, 179–180
White cell abnormalities: in malignancy, *Nov.*, 753–754
Wiring, jaw, for obesity, *July*, 520–521

comparison to behavioral treatment, *July* 527
Work in heat (*see* Heat, work in)
Worksite programs: for behavioral treatment of obesity, *July*, 508

X

X-ray imaging (*see* Radiation, diagnostic)
Xylitol: causing lactic acidosis, *Apr.*, 263–264